Products and methods for controlling the suppression of the neoplastic phenotype

ABSTRACT

A method for gene therapy for cancers wherein chromosomal location of an inactive or defective cancer suppressing gene is established, a replacement gene which is preferably cloned is then used to replace the inactive or defective cancer suppressing gene in the chromosome. In addition to its uses in therapy, the present invention provides a means for prophylactically treating individuals having a genetic predisposition to cancer and provides an animal model for testing for carcinogenicity of environmental substances.

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application is a continuation-in-part patent application of the following pending U.S. patent applications: Title Serial No. Filing Date Human Esterase D, Its Uses and a 091,547 Aug. 31, 1987 Process of Purification ppRB¹¹⁰ nuclear phosphoprotein The 098,612 Sep. 17, 1987 Retinoblastoma Susceptibility Gene Product Retinoblastoma Gene Cancer 108,748 Oct. 15, 1987 Suppressing and Regulator

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] NOT APPLICABLE

REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK.

[0003] NOT APPLICABLE

BACKGROUND OF THE INVENTION

[0004] 1. Technical Field

[0005] This invention relates in general to products and methods for the therapeutic and prophylactic treatment of mammals, to control the phenotypic expression of cancer, and to the production of products and methods for testing for carcinogenicity of environmental substances.

[0006] This invention was made with Government support under Grant No. EY05758 with the National Institute of Health, and the University of California. The Government has certain rights in this invention.

[0007] 2. Background Art

[0008] For many years, cancer in its numerous forms, has been a frightful bane to human society. In many cases, the condition is discovered when the pathological condition has advanced to the point that the patient's life cannot be saved, and the fatal progress of the disease cannot be reversed.

[0009] Some cancerous conditions, if diagnosed and treated in a timely fashion, may be arrested with the life of the patient thereby prolonged. It is the hope of this outcome that motivates cancer patients to spend substantial amounts of money on varying forms of cancer treatment. Because cancer attacks the organism at the elementary, cellular level, through the uncontrolled proliferation of cells, the treatment of cancer has been, historically, dramatic and often destructive of the organism.

[0010] In effect, many treatments for cancer, because they are intended to function dramatically at the cellular level, sometimes themselves destroy healthy cells. Often, destruction of a sufficient number of healthy cells has contributed to, if not caused, death of the patient. Nevertheless, since the patient has only the prospect of imminent death as an alternative, drastic, expensive and life-threatening treatments, such as X-radiation and chemotherapy, have been employed.

[0011] Even when such treatment is successful, the cancer patient remains disabled and ill for significant periods of time after treatment has ceased. Generally, the patient requires hospitalization, not only during the period of treatment, but for significant times thereafter.

[0012] For these reasons, the spectre of cancer has caused great fear in human society. The economic impact, in terms of cost of medical care, combined with the disabling effect of the disease on its sufferers have made the search for reliable methods of diagnosing not only the disease but a predisposition to it, and of treating the disease and/or causing its predisposition very significant.

[0013] Much of the focus of cancer research has been on the diagnosis and treatment of the condition. In recent years, because of advances in knowledge of biochemical processes at the cellular and subcellular level, attention has been directed to methods, not only for diagnosing and treating cancer, but also for discovering a predisposition for cancer in the organism. In order to determine such a predisposition, studies have been done to determine the mechanisms in the body for suppressing cancer.

[0014] In these studies, “cancer suppression” was originally defined by a loss of tumorigenicity observed in fusion cells made with tumor cells and normal fibroblasts, examined, but was undetectable or altered in retinoblastoma cells, Science, 235:1394 (1987), and the mutations within the RB gene have been identified in many cases Science, 236:1657 (1987), and Proc. Natl. Acad. Sci., 85:2210 (1988) and ibid, 85:6017 (1988). This data suggested that the cloned RB gene was tentatively identified.

[0015] A protein product of the RB gene was previously identified as a nuclear phosphoprotein of about 110 kd (pp110^(RB)) using antibodies generated against selected epitomes predicted from the RB cDNA sequence, Nature, 329:642 (1987).

[0016] In light of the evidence establishing the cancer suppression properties of the RB gene, work has been done to utilize the RB gene in the determination of the susceptibility to retinoblastoma as a diagnostic tool. These diagnostic methods and products are disclosed in pending U.S. patent application Ser. No. 108,748, which describes cloning, isolation, identification and sequencing of the RB gene. In addition, said patent application also discloses the method of use of the cloned retinoblastoma gene cDNA as a tool for diagnosing retinoblastoma, osteosarcoma and fibrosarcoma.

[0017] Additionally, pending U.S. patent application Ser. No. 098,612, discloses a phosphoprotein ppRB¹¹⁰ which is primarily located in the cell nucleus and has DNA binding activity. As with RB mRNA, this protein was detected in many types of cultured human cells. pp110^(RB) has been shown to form a tight association with large T antigen and E1A, the transforming proteins of DNA tumor viruses SV40 and adenovirus respectively, Nature, 334:124 (1988); Cell, 54:275 (1988). The RB gene product, or a complex containing it, has been found to have DNA binding activity, Nature, 329:642 (1987). These studies indirectly suggested that pp110^(RB) has a role in regulating the expression of other cellular genes, and may also mediate the oncogenic effects of some viral transforming proteins.

[0018] Much of the current cancer research is directed toward the detection and a predisposition in the organism toward development of cancer. Therefore, it would be highly desirable if a prophylactic method of cancer treatment existed so that tumorigenesis could be arrested before its inception or, even more importantly, foreclosed from development altogether.

[0019] In this regard, in pending U.S. application Ser. No. 091,547, there is described methods for using cloned human esterase D cDNA as a genetic marker as a diagnostic tool for retinoblastoma, Wilson's disease, and other hereditary or acquired diseases controlled by genes located at the 13 chromosome 13q:1411 region. The patent application discloses an esterase D cDNA probe for cloning the retinoblastoma gene, and the use of the cloned human esterase cDNA as a prognostic tool for determination of genetic predisposition to retinoblastoma or Wilson's disease.

[0020] Thus, although significant advances are being made in the development of prognostic tools for determination of the genetic predisposition to cancer, therapeutic and prophylactic treatment of cancer still present the serious foregoing-mentioned limitations. In this regard, the prognostic tool is extremely useful in screening a population, to determine which persons may have a predisposition toward cancer. Thus, once a person is determined by means of the diagnostic tool as having such a predisposition, the person can be monitored at short intervals for the early signs and symptoms of cancer. If such is found, appropriate procedures, such as surgery, can be undertaken at an early date.

[0021] However, while the use of diagnostic tools for the predisposition toward cancer is highly advantageous, the knowledge of such a predisposition is not helpful in the situation where a patient is determined by conventional examination techniques to have, for example, an advanced stage of cancer. In these cases, conventional procedures and treatments have not proven to be entirely satisfactory.

[0022] Therefore, it would be highly desirable to have prophylactic and/or therapeutic treatments for cancer, by utilizing biotechnical techniques. Moreover, it would be important to have such biotechnical modalities, which are effective for many different forms of cancer, with little or no side effects. It would also be desirable to have techniques for proving that certain environmental substances, such as cigarette smoke, cause cancer. Having this type of information could also be used to help people avoid coming into contact with cancer causing substances, since these substances would be proven, rather than merely suspected, of playing a role in oncogenesis.

BRIEF SUMMARY OF THE INVENTION Disclosure of Ivention

[0023] It is a primary object of this invention to provide generally safe and specific therapeutic and prophylactic methods and products useful for controlling cancer suppression.

[0024] It is a further object of this invention to provide products and methods of controlling cancer suppression which are specific for eradication of the cancer tumor by utilizing biotechnical methods and products.

[0025] It is a still further object of the present invention to provide a pharmaceutical composition for therapeutic treating or prophylactic treating of cancer whose active ingredient consists of a natural or replacement gene.

[0026] It is still another object of this invention to provide a pharmaceutical composition for treating and/or prophylactic treatment of cancer whose active ingredient consists of a natural and/or replacement cancer suppressing gene.

[0027] It is still another object of this invention to provide a pharmaceutical composition for treating and/or prophylactic treatment of animals having retinoblastoma or genes having defective, mutant or absent RB genes wherein the active ingredient is a natural and/or cloned replacement non-defective RB gene or gene fragment.

[0028] It is still another object of the present invention to provide animal models which have defective, mutative or absent cancer suppressing genes.

[0029] It is still another object of the present invention to provide methods and products for determining that certain agents and substances cause cancer.

[0030] The present invention comprises a method for gene therapy for cancers wherein chromosomal location of an inactive or defective cancer suppressing gene is established. A replacement gene which is preferably cloned is then used to replace the inactive or defective cancer suppressing gene in the chromosome. In addition to its uses in therapy, the present invention provides a means for prophylactically treating individuals having a genetic predisposition to cancer and provides an animal model for testing for carcinogenicity of environment influences. The term “influences,” as used herein, is intended to be interpreted in a broad sense so that the term includes, but is not limited to, various forms of radiation and various types of substances found in the environment.

[0031] The present invention provides a method of treating cancer which reduces the need for radiation and/or chemotherapy. In addition, it may be employed at a very early stage, after a genetic predisposition to cancer has been discovered, but before the onset of tumorigenesis.

[0032] A further advantage of the present invention is that it utilizes genetic materials which are smaller than entire chromosomes and are generally more stable and more easily clone.

[0033] In the invention of the composition and method herein disclosed it was hypothesized that if the neoplastic behavior of tumor cells were suppressed by an intact RB gene, RB gene inactivation could then be strongly imputed as an important event during tumorigenesis.

[0034] While there is some uncertainty as to whether inactivation of one or more cancer suppressing genes in a cell is sufficient to cause cancer, replacement of inactivated suppressing genes in tumor cells is a novel approach for the treatment of malignancy. Unlike conventional, cytotoxic cancer therapies, gene therapy is premised on permanent correction of an underlying defect in tumor cells. Further, gene therapy may be utilized prophylactically because cancer suppressing genes do not harm normal cells.

BRIEF DESCRIPTION OF THE DRAWINGS

[0035] The above mentioned and other objects and features of this invention and the manner of attaining them will become apparent, and the invention itself will be best understood by reference to the following description of the embodiment of the invention in conjunction with the accompanying figures wherein:

[0036]FIG. 1A and FIG. 1B show the method of production of the Rb virus and the Lux virus;

[0037]FIG. 2A is a chromatogram indicating the presence of normal-sized RB protein in cell lines after infection with RB virus and G418 selection;

[0038]FIG. 2B show photographs of indigenous RB proteins localized in the nucleus in U-20S cells;

[0039]FIG. 3 shows cultures of RB and Lux virus infected tumor calls after G418 selection;

[0040]FIG. 4 shows graphs of WERI-Rb27, Saos-2 and U-20S call colony growth over a five day period; and

[0041]FIG. 5 is a chromatograph showing loss of RB protein expression in nine Saos-2 clones.

BEST MODE FOR CARRYING OUT THE INVENTION

[0042] All references cited in this application are hereby incorporated by reference and made part of this application.

[0043] The detailed description is arranged according to the following outline:

[0044] A. INTRODUCTION

[0045] B. INITIAL STEP OF IDENTIFYING CANCER SUPPRESSING GENES

[0046] B1. IDENTIFICATION OF THE MARKER GENE

[0047] B2. MAPPING OF THE ESD GENE

[0048] B3. CLONING THE ESTERASE D GENE

[0049] C. GENETICS OF ONCOGENICITY AND CLONING OF CANCER SUPPRESSING GENE

[0050] C1. GENETICS OF RETINOBLASTOMA

[0051] C2. MOLECULAR CLONING OF GENES

[0052] C3. IDENTIFICATION OF THE RB GENE BY CHROMOSOME WALKING

[0053] C4. THE RB GENE IN OTHER CANCERS

[0054] C5. CLONING THE RB GENE

[0055] C6. ONCOGENICITY BY MUTANT RB GENES

[0056] D. DIAGNOSTIC PROCEDURES UTILIZING CANCER SUPPRESSING GENE PRODUCTS

[0057] D1. DIAGNOSTIC PROCEDURES FOR DETERMINING CANCER PREDISPOSITION

[0058] D2. IDENTIFICATION AND FUNCTION OF THE RB PROTEIN

[0059] D3. LOCALIZATION AND FUNCTION OF THE ppRB¹¹⁰

[0060] D4. REGULATORY FUNCTION OF ppRB1¹⁰

[0061] D5. ppRB¹¹⁰ AS A DIAGNOSTIC TOOL

[0062] E. GENE THERAPY AND PROPHYLAXIS

[0063] E1. PRODUCTION OF Rb AND LUX VIRUS INFECTION OF TUMOR CELL LINES

[0064] E2. USE OF THE RB GENE IN CANCER SUPPRESSION

[0065] E3. SUPPRESSION OF ONCOGENICITY IN VITRO AND IN VIVO BY THE RB GENE

[0066] E4. TRANSFORMATION BY INACTIVATION OF RB GENES

[0067] F. ANIMAL MODELS FOR EVALUATING SUSPECTED ENVIRONMENTAL INFLUENCE CARCINOGENICITY

DETAILED DESCRIPTION OF THE INVENTION

[0068] Introduction

[0069] The present invention relates to the diagnosis and treatment of cancer as well as providing techniques for determining carcinogenicity of environmental influences. The diagnostic techniques of the present invention are based on determining the susceptibility of a patient to cancer, in some cases before a cancer phenotype is expressed. In general, the diagnostic methods include determination of the chromosomal locus of a cancer suppressing gene. After the locus has been established, techniques have been devised for determining whether or not the cancer suppressing gene is present or absent, and, if present, whether the cancer suppressing gene is fully functional.

[0070] After the locus of the cancer suppressing gene has been established and the gene has been found to be present, the function of the gene can be determined by observation, under controlled circumstances, of the phenotypic expression of the gene. Once technique for evaluating phenotypic expression is to test for the presence of the cancer suppressing gene's product. A preferred technique is to develop an antibody for the gene product which is capable of forming an immunocomplex with the product thereby providing an accurate test for the presence and amount of protein of gene product in a tissue sample.

[0071] Also, after the cancer suppressing gene chromosome location has been established, the gene itself can be cloned and subsequently used as a pharmaceutical product according to the therapeutic methods of the present invention. In this regard, the cloned cancer suppressing gene has a utility in addition to its therapeutic applications since it may also be utilized prophylactically. In this regard, cancer suppressing gene function may be determined prior to any expression of the cancer phenotype in the individual and, if gene deficit or absence is determined, a healthy cloned cancer suppressing gene can be utilized prophylactically in the place of the absent or defective gene.

[0072] Additionally, the present invention relates to the production of a mouse model which has been genetically altered so that the model can be utilized as a reliable method for evaluating carcinogenicity of environmental influences such as tobacco smoke, food preservatives, sugar substitutes and the like.

[0073] The present invention builds upon specific examples the inventions disclosed and claimed in the previously mentioned pending U.S. patent applications. The invention herein disclosed, and those disclosed and claimed in the pending applications, are based on the substantial body of scientific evidence with indicates that carcinogenesis is associated in some manner with genetic alterations and tumor cells. These alterations may be due to mutation, gene inactivation, suppression, deletion or other causes.

[0074] While specific, relevant aspects of the pending applications will be discussed in more detail below, it is worthwhile initially to summarize how each represents a progressive step in establishing the foundation for the present invention.

[0075] The present invention, and those disclosed in the pending applications, are based on the substantial body of scientific evidence which indicates that carcinogenesis is associated with genetic alterations in tumor cells. These alterations may be due to mutation, gene inactivation, suppression, deletion or other causes.

[0076] With genetic alteration as the hypothetical cause of carcinogenesis, it is important to establish the locus and cause of genetic alterations. In addition, it is important to find ways to prevent such genetic alterations by prophylactic measures. Further, the development of models, such, as animal models, to test for carcinogenicity of environmental influences would be useful.

[0077] Considering now the diagnostic method of the present invention in greater detail, the process began with the identification of the amino acid sequence of human esterase D and the nucleotide sequence of esterase D cDNA. Esterase D is important because its genetic locus coincides with the location of the retinoblastoma gene (RB). Thus, cloned esterase cDNA is useful as a genetic marker and as a diagnostic tool for retinoblastoma, Wilson's disease and other hereditary or acquired diseases controlled by genes located at the 13 chromosome 13q14:11 region.

[0078] In addition to its use as a diagnostic tool, cloned esterase cDNA is useful as a probe to clone the RB, and as a prognostic tool for retinoblastoma, Wilson's disease and other diseases controlled by genes located at the 13 chromosome 13q14:11 region.

[0079] Because esterase D and the retinoblastoma gene are located in the same chromosomal region, evaluation of RB gene function, and its chromosomal patterns, was possible. By chromosomal walking, using the esterase D cDNA clone as the starting point, the RB gene was isolated and its nucleotide sequence was determined.

[0080] It is believed that the RB gene has a regulatory function and that its presence and normal function prevents the development of retinoblastoma. On the other hand, absence, malfunction or inactivation of the RB gene causes the development of, or genetic predisposition and susceptibility to, retinoblastoma. Further, it is believed that RB gene absence, malfunction or inactivation is the primary cause, not only for hereditary and acquired retinoblastoma but for other cancers as well.

[0081] Thus, identification of the exact RB gene location and isolation, identification, sequencing and cloning of the RB gene provided a capability for diagnosis and treatment of retinoblastomas and their secondary tumors. It also provided a method for diagnosis and treatment of other cancers related to RB gene function.

[0082] Considering further the diagnostic method of the present invention, an advance in the diagnosis of retinoblastoma, and a predisposition toward retinoblastoma and other cancers, occurred with the identification of a phosphoprotein. The phosphoprotein is associated with DNA binding activity located in the nucleus. The phosphoprotein, identified as ppRB¹¹⁰, plays a role in inhibiting the oncogenic activity of genes other than the RB gene and, in addition, it restrains malignant cell growth.

[0083] The identification, isolation, and determination of the nucleotide sequence and cloning of the RB gene, together with the identification of its phosphoprotein product has many uses.

[0084] An important primary utility lies in the capacity for preparing RB gene protein product which can then be used as an antigen in obtaining specific anti-protein antibody. This antibody can be used as a diagnostic immunomarker for the investigation of the presence or absence of the RB gene protein in examined tissue. If the protein is present, the RB gene is intact and retinoblastoma is not present. If, on the other hand, the protein is absent or altered, the deficient RB gene is indicated and resulting retinoblastoma or other cancers or susceptibility to them is diagnosed.

[0085] There are now two approaches whereby diagnosis of retinoblastoma and other related cancers can be performed. In the first, the RB cDNA or genomic DNA is used as a probe to determine whether a deficit exists in the chromosomal locus of the RB gene. Alternatively, immunoscreening of tissue biopsy with specific anti-ppRB¹¹⁰ antibody is also practical. Both diagnostic methods have application for screening families with a history of hereditary retinoblastoma and for screening of their children. In addition, the methods may be used for prediction of development of secondary cancer, such as osteosarcoma, fibrosarcoma, glioblastoma, breast cancer and others, whether or not connected with retinoblastoma.

[0086] Considering now the therapeutic methods of the present invention, tumorigenesis can be suppressed by providing cloned cancer suppressing genes, such as RB genes, or the cancer suppressing gene protein product, such as ppRB¹¹⁰, after a defective, inactive or absent cancer suppression gene has been diagnosed. These substances can be provided through molecular induction or gene transplanting of RB cDNA to the individual in need. Thus, these methods, in addition to their prophylactic value, have application to a method of arrest of tumor development in the individual.

[0087] Considering further the development of animal modules, in addition to the use of cancer suppressing genes and their related proteins, in diagnostic, prophylactic and therapeutic applications, it is possible to utilize the methods herein disclosed to establish animal models for studying cancer suppressing gene function. As an example, mutant mice have been developed with one inactive allele of the RB gene. These animals are useful in further elucidating the role and significance of the cancer suppressing gene.

[0088] In addition, because “heterozygosity” appears to be the condition precedent to tumorigenesis, the mutant mice become useful models in testing for carcinogenicity of environmental substances. Thus, for example, such mice could be exposed to cigarette smoke, artificial sweeteners or a myriad of other suspected carcinogens. Tumor development in the mice would be a positive indication of the carcinogenicity of the substance tested. The availability of the mutant mouse models thus provides a means for determining which environmental substances should be avoided.

[0089] In addition to their value as models for testing environmental substances, the mutant mouse models have value in cancer therapy studies.

[0090] It should be understood that the basic concepts discussed herein are useful in isolating, cloning and utilizing genes other than the RB gene and have application to other cancer suppressing genes as well. Following are more detailed explanations of each state of the process discussed above together with detailed examples of utilization of the RB gene.

[0091] Initial Step of Identifying Cancer Suppressing Genes

[0092] In order to identify and clone cancer suppressing genes a known chromosome associated with a particular cancer is identified. In general, the chromosome carrying the defective cancer suppressing gene may be determined by examination of phenotypic expression in the absence of the chromosome. Further, such examination can be performed after a portion of the suspected chromosome has been altered by chemical or other techniques or by excision of portions of it. In general, understanding of the control of genetic expression has been based largely on the introduction of genes or other defined segments of DNA into cells and the assessment of the genes' ability to function normally.

[0093] Once a chromosome is selected, the locus is selected on the chromosome for the cancer suppressing gene to be determined. This is accomplished, for example, by the use of probes inserted at random at suspected location of the chromosome in order to establish the location of the gene. This technique is limited because of the large number of genes associated with a typical eukaryotic cell chromosome.

[0094] Secondly, the chromosomal DNA containing the suspected gene may be cut into fragments, for example, by mechanical excision, or by use of suitable restriction enzymes, or other means. This technique may be employed to establish gene location by, once again, ultimately evaluating the phenotypic expression of the DNA fragments.

[0095] Thirdly, a preferred method of identifying the location of the cancer suppressing gene is through the utilization of a marker gene. Ideally, the marker gene is located in close proximity to the locus of the cancer suppressing gene and, in addition, the marker gene is a readily observable phenotypic expression. Once the marker gene has been identified, chromosomal walking techniques are employed in order to analyze portions of the chromosomal DNA in order to locate the cancer suppressing gene. Chromosomal walking depends on isolating a small segment of DNA from one end of a first recombinant and using this piece of DNA as a probe to rescreen the phage or cosmit library in order to obtain a recombinant containing that piece of DNA and the net portion of the genome.

[0096] The second recombinant is then used to obtain a third, and so in, to yield a set of overlapping cloned segments. In general, the chromosome walking technique may be utilized bidirectionally along the chromosome, starting with the marker gene.

[0097] Identification of the Marker Gene

[0098] An actual example of the use of a marker gene was the identification, purification and cloning of the esterase D gene. Chromosome mapping of the esterase D gene to the chromosome 13q14.11 region was accomplished by correlating loss of the esterase D gene activity with known deletions on chromosome 13 of mutant cells.

[0099] Since it was known that the esterase D gene was located in close proximity to the RB gene, it was used as a starting point for identifying the RB gene by chromosomal walking. Because of its proximity to the RB gene, the esterase D gene was ideal as a marker gene. Not only did its proximity reduce the chromosomal walking necessary to locate the cancer suppressing gene, genetic alterations of the esterase D gene would result in, not only an altered esterase D gene phenotype but, in addition, an altered cancer suppressing gene phenotype.

[0100] In the development of the marker gene, the amino acid sequence of human esterase D enzyme was identified as was the nucleotide sequence of esterase D cDNA. The chromosomal location of the gene was located and cloned esterase D cDNA was utilized as a genetic marker.

[0101] The use of the marker, as a starting point for chromosomal walking and the further use of the esterase D cDNA as a probe resulted in the location and cloning of the retinoblastoma gene.

[0102] While the following summarizes the utilization of human esterase D cDNA as a genetic marker, for a complete disclosure of the method, reference may be made to pending patent application Ser. No. 091,547.

[0103] Esterases belong to the family of nonspecific enzymes that catalyze the hydrolysis of esters. Human esterase D (ESD) is one member of the esterase family distinguishable by its electrophoretic mobility and its relative specificity for methylumbelliferyl esters as substrate. Human ESD is a dimeric enzyme in that it displays several phenotypes as a result of the expression of codominant autosomal alleles, primarily allele ESD 1 and ESD 2. The polymorphic nature of human ESD has been of value in the use of human ESD as a marker in studies of population genetics Nature, 304:451-453 (1983); and Am. Hum. Genet., 39:1-20 (1975).

[0104] The activity of ESD enzyme depends on the normal function of the ESD gene. Consequently, absence, complete or partial inactivation, deletion of one ESD allele, mutation or other alterations in ESD sequences will result in decreasing ESD activity. For example, the tissues of individuals with a deletion of one chromosome 13 show only 50% of the ESD activity of that found in the healthy individuals possessing a normal set of two chromosomes 13, Science, 219:973-975 (1983).

[0105] The genetic locus of ESD was mapped to the chromosome 13q14:11 region by correlating the loss of enzyme activity with deletions of chromosome 13, Science, 208:1042-1044 (1980). The regional assignment of ESD to 13q14:11 region coincides with the location of the retinoblastoma (RB) gene, shown to be involved in the tumorigenesis of retinoblastoma, Am. J. Dis. Child., 132:161-163 (1978); Science, 219:971-973: Science, 213:1501-1503 (1981). The development of homozygosity or hemizygosity in the 13q14 region by deletion, mitotic recombination, or chromosomal loss has been interpreted as a primary event in retinoblastoma. This finding is consistent with the hypothesis that inactivation of both alleles of a gene located at 13q14:11 is required for tumorigenesis.

[0106] By examining levels of esterase D mapping to the 13q14.11 region, it was previously inferred that one chromosome 13 in the somatic cells of the retinoblastoma patient contained a submicroscopic deletion of the RB and esterase D loci and that this chromosome was retained in the tumor, while the normal chromosome 13 was lost, Cancer Gen. Cytogen, 6:213-221 (1983).

[0107] The localization of the ESD and RB genes in the same chromosomal region provides an advantageous approach for evaluation of the RB gene functioning, for discovery of RB chromosomal patterns, for cloning of the RB gene, for isolation of the RB gene and for identifying the RB gene sequence by chromosomal walking, using ESD as the starting point Science, 235:1394-1399 (1987). The tight linkage between these two genes allows the ESD gene to serve as a crucial marker in elucidating the behavior of the RB gene, Science, 219:973-975 (1982): and Nature, 304:451-453 (1983).

[0108] Other than the RB gene, the defective gene in Wilson's disease has been found to be located in the same chromosomal region, 13q14:11, and thus was found to be linked to the ESD gene, Proc. Natl. Acad. Sci., 82:1819-1821 (1985). Wilson's disease, also known as hepatolenticular degeneration, is a hereditary disease of ceruloplasmin formation transmitted as an autosomal recessive. It is characterized by gross reduction in the incorporation of copper in ceruloplasmin resulting in decreased serum ceruloplasmin and copper values, and increased excretion of copper in the urine. The close linkage found between Wilson's disease locus and the ESD gene, which can serve as the polymorphic marker for Wilson's disease, has profound implications both for investigation of the primary gene defect and for clinical use.

[0109] The identified and cloned ESD cDNA thus would provide a valuable marker in the identification and sequencing of both the RB gene and the Wilson's disease gene would lead, eventually, to diagnosis and treatment of these disease.

[0110] In the pending U.S. patent application Ser. No. 091,547, a process was disclosed for purifying human ESD by first obtaining the human ESD from human tissue, lysing said tissue, extracting the lysed tissue with an organic solvent, partially purifying the extract and then separating the purified ESD by column chromatography.

[0111] The purified human ESD obtained was subsequently used in the preparation of specific rabbit anti-esterase antibody.

[0112] The antibody was utilized to identify and isolate ESD cDNA clones through a technique for cloning genes by using specific antibody as probes and for isolating unknown proteins encoded by cloned DNA. In general, the method used an expression vector λgt11 (lac5 nin5 cI857 S 100_that permitted insertion of foreign DNA into β-galactosidase structural gene lac Z and promoted synthesis of hybrid fusion proteins, DNA, 3:437-447 (1984).

[0113] B2. Mapping of the ESD Gene

[0114] Chromosome mapping of the ESD gene to the chromosome 13q14.11 region was accomplished by correlating loss of the ESD enzyme activity with known deletions on chromosome 13 of various mutant cells. In addition, analysis supported the conclusion that the EL22 clone containing the esterase D gene was mapped to the chromosome 13q14 region.

[0115] Using the esterase D cDNA as probe, it was found that (i) the size of the esterase D mRNA is 1.3-1.4 kb; (ii) the gene is around 20-35 kb, indicating the presence of large introns scattered over this genome; and (iii) the esterase D gene is indeed located at 30 chromosome 13q14 region. Also, the deduced amino acid of the esterase D gene was unique when compared to 4000 other well-characterized proteins.

[0116] The above mapping data shows that the ESD gene is located at chromosome 13q14.11 region with no meiotic recombination observed with the RB gene. These findings indicate that both genes are in close proximity although the exact kilobase-pair distance between them is unknown. Normally, the maximal DNA content of a band, such as q14:11 does not exceed, on the average, 1000 kb. On the other hand, the distance, between the RB gene and the ESD gene may be just a few kilobases.

[0117] Based on the lack of esterase D activity in LA-RB 69 retinoblastoma cells, it has been suggested that a submicroscopic deletion had occurred in the tumor cells resulting in the loss of both the RB and the esterase D genes. It was believed that some abnormality, perhaps in the regulatory region, must occur to cause a substantial reduction in the expression of the esterase D gene and diminution of the enzyme activity. It was plausible to expect that this abnormality would be likely to interfere with the RB gene expression leading to tumorigenesis.

[0118] B3. Cloning the Esterase D Gene

[0119] Since the genetic locus involved in the genesis of retinoblastoma is tightly linked to the esterase D gene, it was crucial to clone the esterase D gene. The availability of the completely sequenced cDNA clone and ESD gene facilitated retinoblastoma studies in that it allowed the identification of the RB gene, its cloning and sequencing, and thus enabled a clinical diagnosis of retinoblastoma and genetic corrections.

[0120] Recently, the human esterase D was successfully purified. The polyclonial anti-esterase D antibody was prepared, and oligonucleotide probes complementary to certain ESD polypeptides were constructed. The complete amino acid sequence of ESD protein was determined, and ESD cDNA was cloned. The complete nucleotide sequence of both ESD cDNA and the ESD gene were identified and the ESD gene was localized.

[0121] In addition, specific human anti-esterase D antibody was able to bind a polypeptide with a molecular mass of about 33-34 kDa subsequently identified as ESD.

[0122] Using this anti-esterase D antibody, a protein corresponding to human esterase D was immunoprecipitated from mouse, rat, hamster, and monkey cells.

[0123] The above described immunologic reaction was then used in identification and the isolation of the ESD cDNA clones from two λgt11 cDNA libraries. The technique of cloning genes by using specific antibody as probes and for isolating unknown proteins encoded by cloned DNA is well known. In general, the method uses an expression vector, λgt11 (lac5 nin5 cI857 S 100) that permits insertion of foreign DNA into B-galactosidase structural gene lac Z and promotes synthesis of hybrid fusion proteins, DNA, 3:437-447 (1984).

[0124] It was presumed that since ESD was shown to be present in many bodily tissues, the mRNA coding for ESD would be readily present in tissue extracts and/or in certain tissue tumors. Human hepatoma and human placenta tumors both have a relatively high level of expression of ESD mRNA and were, therefore, particularly suitable for the detection of specific ESD cDNA clones in the library. Therefore, these two tumors were chosen for construction of the ESD cDNA libraries in λgt11 vector.

[0125] Following immunoscreening of these libraries with anti-esterase D antibody, four clones were obtained. Two of the clones, with identical 1.1 kb (1100 bp) inserts, were called EL22a and EL22b. After analysis it was concluded that the EL22 clone is, in fact, the esterase D cDNA.

[0126] To determine the size of ESD mRNA, RNA blotting analysis was performed and the size of mRNA of two cell lines was found to be ≈14.5 S(1.3-1.4 kb).

[0127] A distribution of the ESD gene in the human genome was determined by Southern genomic blotting analysis using ³²P-labeled EL22 clone. It was found that the esterase D gene was distributed over 20-40 kb in the human genome. The combined size of the DNA fragments with positive hybridization was 20-40 kb, indicated that there are large intron sequences in the ESD genome. This was subsequently confirmed by characterizing the complete genomic esterase D clone.

[0128] C. Genetics of Oncogenicity and Cloning of Cancer Suppressing Gene

[0129] After identifying and cloning the marker gene, its associated cancer suppressing gene is then identified and cloned. Chromosomal walking techniques are utilized to locate the cancer suppressing gene to be found. While the examples herein disclosed relate to use of the esterase D gene as a marker and of the evaluation of the RB gene in oncogenicity, it is understood that the examples disclosed herein will equally apply to the marker genes and the respective cancer suppressing genes as breast cancer suppressing genes, Wilm's tumor suppressing genes, Beckwith-Wiedemann syndrome suppressing gene, bladder transitional cell carcinoma suppressing gene, neuroblastoma suppressing gene, small cell lung carcinoma suppressing gene, renal cell carcinoma suppressing gene, acoustic neuroma suppressing gene, colorectal carcinoma suppressing gene, and others.

[0130] The chromosome walking technique performed as previously described can be utilized for location identification, purification and cloning of the above cancer suppressing genes. In general, analysis of the cancer suppressing gene activity can be determined by observation of the gen's phenotypic expression.

[0131] C1. Genetics of Retinoblastoma

[0132] As an example of the practice of the present invention, the RB gene role in suppressing retinoblastoma has been determined.

[0133] The genetic control of retinoblastoma and suppression of carcinogenicity were evaluated by means of the cloning, isolation, identification and sequencing of the retinoblastoma gene. The cloned retinoblastoma gene cDNA was prepared and used as a tool for diagnosing retinoblastoma, osteosarcoma and fibrosarcoma. Development of the retinoblastoma gene led to the therapeutic application whereby a defective gene in cancer cells may be replaced with a normal gene thereby suppressing cancer formation.

[0134] While the following summarizes the method of development of the retinoblastoma gene, for a complete disclosure, reference may be made to pending patent application Ser. No. 108,748.

[0135] It is increasingly evident that carcinogenesis is associated with genetic alterations in tumor cells. Some of these alterations may occur in precursor somatic cells during the life of an individual, while other mutations might be inherited from a parental germline. The latter type of inheritance would explain cases of familial cancer and inherited cancer predisposition. Cancers with known familial occurrence include retinoblastoma, nephroblastoma (Wilm's tumor), neuroblastoma, osteosarcoma, renal cell carcinoma, melanoma, and breast cancer.

[0136] Several approaches have been applied to identify genetic elements involved in tumorigenesis. Oncogenes were initially defined in tumor-inducing retroviruses and tumor DNA capable of transforming non-neoplastic cells in culture. Most oncogenes are activated homologues of protooncogenes that exist in normal cells.

[0137] Another class of cancer genes has been proposed for which lose of gene function is associated with oncogenesis. The existence of such genes was first indirectly suggested by studies with restriction fragment length polymorphisms (RFLPs) that indicated a loss of specific chromosomal regions in tumor DNA compared to somatic DNA from the same patients. The “loss of heterozygosity” has been observed in many tumor types including retinoblastoma, osteosarcoma, Wilm's tumor, hepatoblastoma and rhabdomyosarcoma.

[0138] Genes giving rise to tumors by loss of function have been termed “recessive oncogenes” or “cancer suppressing genes” since the presence of one or more normal alleles in a cell is apparently sufficient to prevent expression of the cancer phenotype.

[0139] Retinoblastoma is an intraocular cancer of early childhood that arises from the developing retina. It has been reported that its incidence is about 1 in 20,000 live births and it is the most common intraocular tumor of the pediatric age group. Two forms of retinoblastoma are distinguished on a genetic basis. The hereditary form is an autosomal-dominant cancer susceptibility trait: each offspring of a carrier parent has a 50% chance of inheriting the trait, and 90% of carriers will develop retinoblastoma. Multiple or bilateral retinal tumors are indicative of, and typical for, hereditary retinoblastoma. Furthermore, carriers are at high risk of developing additional primary neoplasms later in life; these second cancers are of otherwise unusual types, such as osteosarcoma or fibrosarcoma, and are usually fatal. In contrast, patients with nonhereditary retinoblastoma have single, unilateral retinal tumors and no increased risk of second cancers. However, some of the patients with unilateral retinoblastoma actually have the hereditary form. Because of its clear-cut inheritability, retinoblastoma has been a prototypic model for the study of genetic determination in cancer.

[0140] It has been inferred that retinoblastoma could result from as few as two “hits”, or mutational events and it has been hypothesized that two hits served to inactivate both alleles of a singe gene (RB) that essentially functioned to suppress retinoblastoma formation. An individual inheriting a mutant RB allele in all somatic cells would be predisposed to getting retinoblastoma by an additional mutation of the other RB allele in one precursor cell (retinoblast). In sporadic cases, both RB alleles would have to be inactivated by two independent somatic mutations in a single retinoblast. This model could explain both the earlier onset and multiplicity of tumors in predisposed individuals. However, the validity of this hypothesis remains to be demonstrated at the molecular level.

[0141] Karyotypic examination of somatic cells (fibroblasts) from patients with hereditary retinoblastoma disclosed a minor subset of cases containing visible deletions of the long arm of chromosome 13. Similar deletions were also identified in retinoblastoma tumor cells. Studies of a large retinoblastoma pedigree show that normal individuals carried a balanced translocation involving 13q14, while those with retinoblastoma had only one 13q14 region. Band 13q14 was common among all deletions and presumably contained a gent (RB) determining susceptibility to hereditary retinoblastoma; these deletions also removed one allele of the gene for a polymorphic marker enzyme, esterase D.

[0142] It is known that the RB gene has a regulatory function and that its presence and normal function prevent the development of the retinoblastoma. On the other hand, absence, malfunctioning or inactivation of the RB gene causes the development of, or genetical predisposition and susceptibility to, the retinoblastoma and is believed to be the primary cause for both hereditary and acquired retinoblastoma, and for the secondary malignancies often recurring in retinoblastoma patients such as osteosarcoma, and fibroblastoma.

[0143] Therefore, it is useful to determine if a genetic predisposition exists in a fetus or if there is a susceptibility for acquiring retinoblastoma at a later age so that early diagnosis and possible treatment though genetic manipulation could be accomplished.

[0144] C2. Molecular Cloning of Genes from Chromosome Region 13g14

[0145] Since nothing was known a priori about the RB gene product, candidate genes were to be identified solely on the basis of appropriate chromosomal location and presumed “recessive” behavior. That is, an intact RB gene should be expressed in normal retinal tissue but not in retinoblastomas. “Reverse genetic” cloning strategies require a collection of one or more DNA probes from the region of interest. These may consist of probes for other known genes; or of anonymous DNA probes isolated at random by a number of techniques. Before attempting to clone the RB gene, several laboratories made major efforts to obtain probes for region 13q14. The polymorphic marker enzyme esterase D was mapped to 13q14 and is closely linked to the RB gene with no known recombinants. By generating specific antisera and partially sequencing the protein, esterase D cDNA fragments have been identified. Also available were anonymous DNA probes mapping to 13q14, such as H3-8, H2-42 and 7D2 that were isolated by random selection from chromosome 13-specific libraries.

[0146] After identification of the RB gene its cDNA sequence and genomic organization were determined. Pending U.S. patent application Ser. No. 098,612 discloses the amino acid sequence of a phosphoprotein located in the cell nucleus and having DNA binding activity.

[0147] C3. Identification and Role of the RB Gene by Chromosomal Walking

[0148] The esterase D gene has been located, identified, sequenced and cloned. Further, it has been located in close vicinity to the RB gene. Therefore, it is useful as the starting point for identifying the RB gene by chromosomal walking. DNA fragments isolated from this process can then be used as probes to examine qualitative or quantitative differences in mRNA from fetal retinal cells and retinoblastoma cells. Detection of such differences would provide evidence that somatic mutations occur in the RB gene of tumor cells. The DNA fragments corresponding to the defective mRNA are the best candidates for the RB gene. Moreover, the availability of mutant cells with known deletion in 13q13.1-14.11 and 13q14.11-q22, respectively, enables determination of the correct direction of walking toward the RB gene.

[0149] Specific esterase D clone EL22 together with another probe H3-8 were mapped to the same chromosome region 13q14 as the known location of the RB gene.

[0150] Bidirectional chromosomal walking along the chromosome 13 DNA was instituted using esterase D and H3-d as probes to clone additional genomic DNA and cDNA. This alternative screening led to the identification of several distinct clones such as SD-1, SD-2, RB-1, RB-2 and RB-5.

[0151] Candidate RB genes were used as probes in RNA blotting to detect mRNA transcripts and clones RB-1 and RB-5 were hybridized with a 4.6 kb mRNA fragment obtained from the normal retinal and placental tissues. Hybridization under the same conditions with mRNA obtained from the retinoblastoma mRNA transcripts was not observed at all.

[0152] Other types of tumors not related to retinoblastoma, namely neuroblastoma and medulloblastoma, displayed normal 4.6 kb mRNA transcripts.

[0153] Two cDNA libraries, placental and fetal retina, were rescreened with clone RB-1 for complete cDNA clone and resulted in the isolating of clone RB-5.

[0154] Additionally, more than 20 phage clones were isolated from a human genomic DNA library with RB-1 and RB-5 as probes and were subsequently characterized by restriction mapping and hybridization to subfragment cDNA probes. A restriction map of the RB gene was then constructed showing that the RB gene consists of at least 12 exons scattered over more than 100 kb of DNA.

[0155] Sequence analysis was performed and yielded the reconstructed complete DNA sequence. Deletion templates were generated which yielded greater than 95% of the sequence.

[0156] The sequence of the RB gene protein products was then predicted and an amino acid hydropathy plot constructed.

[0157] Through the method disclosed in pending patent application Ser. No. 108,748, a gene encoding a messenger RNA (mRNA) of 4.6 kilobases (kb), located in the proximity of esterase D, was identified as the retinoblastoma susceptibility gene on the basis of chromosomal location, homozygous deletion, and tumor-specific alterations in expression. Transcription of this gene was abnormal in six of six retinoblastomas examined. In contrast, full-length RB mRNA was present, in human fetal retina and placenta tumors, and in other tumors such as neuroblastoma and medulloblastoma. DNA from retinoblastoma cells had a homozygous gene deletion in one case and hemizygous deletion in another case, while the remainder were not grossly different from normal human control DNA.

[0158] The RB gene contains 27 exons distributed in a region of over 200 kb. Sequence analysis of complementary DNA clones yielded a single long open reading frame that could encode a hypothetical protein of 928 amino acids.

[0159] A computer assisted search of a protein sequence database revealed no closely related proteins. Features of the predicted amino acid sequence included potential metal-binding domains similar to those found in nucleic acid-binding proteins. These results suggested involvement of the RB gene as a recessive genetic mechanism for regulation of human cancers.

[0160] As indicated above, the initial starting point was the gene encoding esterase D which is linked to the retinoblastoma susceptibility locus in band 13q14.11 within an estimated 1.500 kilobase range. The esterase D cDNA clone EL-22 was used as a probe to isolate its genomic DNA clones. Distal DNA segments of these genomic clones were used to isolate additional genomic clones. At 20 kb intervals in walking regions, unique sequences were identified that were used as probes to isolate cDNA clones from fetal retina and placenta libraries. A similar strategy using H3-8 as probes was performed to isolate the candidate genes. A bidirectional chromosome walk covering hundreds of kb has been established by alternately screening genomic and cDNA libraries.

[0161] Candidate RB genes were used as probes in RNA blotting analysis to detect relevant messenger RNA (mRNA) transcripts polyadenylated RNA was prepared from human fetal retinas (obtained by dissection of about 25 first- or second-transfer fetal eyes) and from portions of normal human placentas. Since the primary retinoblastoma tumor samples large enough to yield sufficient mRNA for analysis are not usually available, polyadenylated RNA was isolated from cultured cells of six retinoblastomas. Additionally, polyadenylated RNA was isolated from three neuroblastomas and one medulloblastoma and from a primary medulloblastoma specimen.

[0162] Esterase D transcripts (1.4 kb) were detected in all tumor and tissue samples. This finding was consistent with the known “constitutive” expression of esterase D. Esterase D hybridization was subsequently used as a positive control.

[0163] Thus, only gross deletions but no small partial deletions of the RB gene were seen in these tumors, and detection of an intact genome did not imply normal gene expression. Such a disparity may be due to mutations in the promotor region. Explanations for decreased mRNA transcript size include small deletions within exons (which might not sufficiently alter gel mobility of large exon splicing sequences or other mRNA processing signals.

[0164] The numerous large Hind III bands seen on DNA blotting analysis suggested that the RB locus was spread over a rather large genomic region. To further clarify genomic structure, more than 20 phage clones were isolated from the human genomic DNA library with RB-1 and RB-5 as probes. These clones were characterized by restriction mapping and hybridization to subfragment cDNA probes. In conjunction with data from genomic DNA blotting, the Hind III restriction map of the RB gene was constructed. The RB gene consists of 27 exons scattered over more than 200 kb of DNA. One large intron of at least 50 kb is located between exons from the RB-1/RB-5 overlap region.

[0165] Recently described, Nature, 323:643-646 (1986) was a cDNA clone with properties that were attributed to the RB gene. This clone detected a 4.7-kb mRNA transcript present in adenovirus 12-transformed retinal cells but absent in four of four retinoblastoma cell lines. Deletions involving part or all of this gene were observed in five retinoblastomas, but none of these were internal homozygous deletions. These findings were not sufficient to precisely identify the RB gene. Sequence data were not included in the report, the restriction map of the cDNA clone was similar to those found in this invention.

[0166] As noted above, the RB gene expression, while specifically altered in retinoblastoma, was not confined to normal fetal retina but was also seen in at least one other normal unrelated tissue, placenta. For a more extensive survey, mRNA from fetal and adult rat tissues were prepared and analyzed by RNA blotting. A 4.6-kb mRNA transcript (presumably the normal size for rat) was detected in all tissues, though quantity varied markedly. A second species of transcript, approximately 2.3 kb in size, was apparent in fetal rat brain. This short transcript may represent either differential processing of the RB gene or transcription of a separate but closely related gene.

[0167] Recently another RB cDNA clone was isolated that contained an additional 234 base pairs on the 5′ end. The revised RB cDNA sequence had an additional methionine codon at nucleotide 139. When this methionine was used as initiation codon, the predicted RB protein had 928 amino acids and a molecular weight of 110 kD. The second in-frame methionine was at base 346. Since the nucleotide sequence at the first ATG is not typical of other known mRNAs, the start codon assignment should be regarded as tentative. Later, the in vitro translation results favored the first methionine as the authentic initiation site. A computer search of the National Biological Research Foundation protein sequence database sequence detected no strong homology with any of more than 4000 published amino acid sequences. However, a number of nucleic acid-binding proteins and viral proteins showed weak sequence homology, with a yeast DNA-directed RNA polymerase having the highest homology score.

[0168] The predicted protein sequence included ten potential glycosylation sites but a candidate transmembrane domain (at least 20 consecutive hydrophobic residues) was not found. The amino acid hydropathy plot showed a mildly hydrophobic region near the putative amino terminus and a hydrophilic region at the carboxyl terminus. Two pairs of short amino acid sequences that were bracketed by cysteine and histidine residues in the manner of metal-binding domains found in nucleic acid-binding proteins were identified. A region of 54 amino acids from position 663 to 716 contains 14 proline residues (26%). Such proline-rich regions have also been observed in nuclear oncogene proteins myc and myb. While the significance of these observations is not well established, they suggested that the RB gene product may be a nucleic acid-binding protein. Subsequently, the RB protein ppRB¹¹⁰ as been found to be primarily located in the cell nucleus.

[0169] The retinoblastoma gene has been previously found to be of a recessive nature. Tumor-specific alterations in gene expression provide the best evidence for identifying this gene as RB, and the examples of homozygous deletion and absence of mRNA expression support its postulated recessive nature.

[0170] Hereditary retinoblastoma patients have a high incidence of osteosarcoma as a second primary cancer. Inactivation of the retinoblastoma susceptibility (RB) gene has been implicated in the genesis of osteosarcoma by chromosomal homozygosity of the 13q14 region found in several osteosarcoma patients with or without retinoblastoma history.

[0171] In view of the above, it is clear that the role of the RB gene in tumor formation is of more general interest than simply that attendant to a rare childhood cancer. First, recessive genes similar to RB may control other unusual embryonal childhood cancers such as nephroblastoma (Wilm's tumor), hepatoblastoma, embryonal rhabdomyosarcoma, and neuroblastoma. Like retinoblastoma, all of these tumors resemble massive overgrowth of tissues found in normal embryogenesis. Nephroblastoma has been associated with deletions of chromosome region 11p13, and adjacent polymorphic markers become homozygous in these tumors.

[0172] C4. The RB Gene in Other Cancers

[0173] Since the sequence of the RB gene is now known, the role of the RB gene in other tumors may now be explored. Retinoblastoma patients have a high rate of second malignancies occurring at a variety of sites. Osteosarcoma is the most common. Reduction to homozygosity in region 13q14 has been reported in osteosarcomas even without prior retinoblastoma, which suggests a common oncogenic mechanism for the two tumors despite their histologic and oncologic dissimilarity. In contrast, neuroblastoma and medulloblastoma, which are considered closely related to retinoblastoma, apparently do not involve alterations of RB. Further study of the RB gene will likely provide insight into unifying mechanisms of oncogenesis.

[0174] By analogy to retinoblastoma, a class of “cancer suppressing genes” has been postulated to explain other types of inherited cancers, and tumor-specific chromosomal deletions. Retinoblastomas and osteosarcomas often occurred in the same patients, and several osteosarcomas (from patients both with and without retinoblastoma history) demonstrated a loss of heterozygosity of chromosome 13 markers. A few breast cancers also showed specific loss of chromosome 13 heterozygosity. Loss of heterozygosity has been found at chromosome lip in Wilm's tumor (consistent with known deletions), tumors of the Beckwith-Wiedmann syndrome, transitional cell carcinoma of bladder, and, again, breast cancer. Similarly, other suppressing loci have been implicated in neuroblastoma, small cell lung carcinoma, renal cell carcinoma, acoustic neuroma, and colorectal carcinomas.

[0175] The RB gene was initially identified on the basis of altered RB gene expression in retinoblastoma tumors compared to that of normal tissues. Many additional tumors and neoplastic cell lines have been examined, and several with either DNA rearrangements, altered RB mRNA, or absent RB protein have been found. For example, of eight osteosarcoma cells lines tested, three (G292, SA0S2 and OHS) showed abnormalities at the protein level. G292 expressed RB protein of increased molecular mass, whereas SA0S2 and OHS completely lacked the RB protein. Both osteosarcoma cell lines without RB protein had shortened RB mRNA transcripts, and G292 had both shortened and normal-sized RB mRNA transcripts. Call line SA0S2 had homozygous deletion of the 3′ end of the RB gene, involving exon-containing Hind III fragments of exons in an internal 7.5 kb Hind III fragment. However, G292 had a grossly normal RB gene structure.

[0176] RB protein was also absent from one synovial sarcoma cell line (GHM) in which norma-sized RB mRNA was present. GHM DNA was also grossly normal by DNA blotting analysis with RB cDNA probes. This cell line constitutes the first known example of RB gene inactivation apparently solely at the protein level. A fresh specimen from a synovial sarcoma tumor, SDSY1, was also analyzed. Both normal-sized and lengthened RB MRNA transcripts (6.5 kb) were observed by RNA blotting and is apparent that normal-sized transcripts may be derived from non-neoplastic cells intermixed in whole tumors. Analysis of SDSY1 DNA with RB cDNA probes showed extra restriction fragments in addition to all normal fragments after digest with Hind III, EcoR I and Pst I endonucleases, suggesting internal RB gene duplication. Duplication of exons in these fragments would add approximately 1.1 kb to the RB mRNA transcript, and would substantially account for the observed mRNA size (6.5 kb). Other studies have confirmed the presence of RB gene mutations in fresh osteosarcomas and a variety of soft-tissue sarcomas from patients without a history of retinoblastoma.

[0177] Recently, RB gene inactivation in two of nine human breast cancer cell lines was found. The RB gene of one cell line had a homozygous internal duplication of 5 kilobase (kb) region containing exons 5 and 6. The RB mRNA transcript was correspondingly lengthened, and it was inferred that its translation was terminated prematurely due to a shifted reading frame. The other cell line had a homozygous deletion of the RB gene that removed the entire gene beyond exon 2. The RB gene product, pp110^(RB), was not detectable in either cell line by immunoprecipitation with specific antibodies. Also reported recently was loss of RB gene expression in some cell lines derived from small cell carcinomas of the lung.

[0178] These results support a role for RB gene mutation in the genesis of cancers other than retinoblastoma. However, for each tumor type, mutations have been detected in only a fraction of cases. There are two possible explanations for this: 1) there is genetic heterogeneity among these tumors, such that only a fraction of each tumor type involves the RB gene; and/or 2) some inactivating mutations of the RB gene are not being detected.

[0179] C5. Cloning the RB Gene

[0180] The identification, isolation, determination of the exact nucleotide sequence and cloning of the RB gene has a multiple utility.

[0181] The primary utility lies in the sequence transcription into its corresponding mRNA which is in turn translated into RB gene protein product. Protein product can then be used as an antigen in obtaining the specific anti-RB protein antibody. Antibody are then used as a diagnostic immunomarker for the investigation of the presence or absence os the RB gene protein in the examined tissue. If the RB protein is present, the RB gene is intact and retinoblastoma not present. If, on the other hand, the protein is absent or altered, the deficient RB gene is indicated and resulting retinoblastoma or other cancers or susceptibility thereto is indicated.

[0182] The sequence of the RB gene can be further utilized in producing the specific RB gene cDNA clones which can be used as the genetic markers and probes in isolation, identification and sequencing of other related genes or genes located in the proximity of the RB gene the function of which is as yet unknown.

[0183] The control and regulatory function of the RB gene is exerted through the RB protein which is instrumental in inhibiting other gene's oncogenic activity and restraining the malignant cell growth.

[0184] C6. Oncogenicity by Mutant RB Genes

[0185] The absence of antigenically detectable RB protein in retinoblastoma cells supports the notion that oncogenicity by mutant RB genes is achieved through complete loss of gene product function even in those cell lines containing shortened RB mRNAs.

[0186] The hypothetical protein predicted from the nucleotide sequence was expected to have MW about 106 kD. The immunoprecipitated protein has a MW about 110-114 kD. The complete RB protein amino acid sequence is illustrated in Table 1. This complete sequence obtained from the newly reconstructed clone which contains the most 5′ end stretch missing in the original cDNA clone Science, 235:1394-1399 (1987). TABLE 1       

PPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPE ( 34) QDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERA ( 74) WLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDE

S (114) FTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKK (154) YDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVS (194) WITFLLAKGEVLQMEDDLVISFQLNLCVLDYFIKLSPPML (234) LKEPYKTAVIPINGSPRTPRRGQMRSARIAKQLENDTRII (274) EVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEV (314) ENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQ (354) RTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASD (394) QPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAV (434) GQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFS (474) KLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSF (514) PWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCE (554) HRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNL (594) PLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATS (634) AFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHP (674) ELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKV (714) KNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIV (754) FYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPS (794) SPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVS (834) IGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKK (874) LRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQ (914) KMNDSMDTSNKEEK (928)

[0187] single-letter abbreviations for the amino acid residues are:

[0188] A, Ala; C, Cys; D, Asp; E, Gly; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

[0189] The amino acid sequence (Table 1) is written in the abbreviation code recognized in the art. Single-letter abbreviations for the amino acid residues are: A=Alanine, C=Cysteine, D=Aspartic acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutanine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophane and Y=Tyrosine.

[0190] RB cDNA sequence Science, 235:1394-1399 (1987) contained a long open reading frame from nucleotide 1 through 2688, which when translated from the first methionine codon yielded a hypothetical protein of 816 amino acids and molecular weight 98 kD. Recently another isolated RB cDNA clone contained an additional 234 base pairs on the 5′end. The revised RB cDNA sequence still maintained the same open reading frame as in the original clones, and an additional methionine codon was found at nucleotide 139. When this codon was used as an initiation codon, the predicted RB protein had 928 amino acids and a molecular weight of 110 kD—identical to the apparent M.W. determined by SDS-PAGE. The additional 5′ sequence contains a GC-rich region that translates into an unusual cluster of alanine and praline residues.

[0191] Discrepancies between actual and apparent molecular weights on SDS-PAGE may be explained by secondary protein modifications. Several potential N-linked glycosylation sites are present in the predicted amino acid sequence. However, when LAN-1 cells were grown in medium supplemented with ¹⁴C-galatose or ³H-glucosamine, labeled RB protein was not detected despite prolonged autoradiography. In addition, digestion of ³⁵S-labeled RB protein by Endoglycosidase H according to the method described in J. Bill. Chem., 250:8569-8579 (1975), did not result in a reduction of apparent molecular weight.

[0192] When the neuroblastoma cells LAN-1 were metabolically labeled with ³²p-phosphoric acid and immunoprecipitated, the immunoprecipated protein ran as a single band with molecular weight identical to the ³⁵S-labeled RB protein. The results show Lanes 2+3 showing a ³⁵S-labeled band at 110-114 kD and Lane 5 -³²P-labeled band at 110-114 kD. Lanes 1 (³⁵S) and 4 (³²P) are immunoprecipitated with preimmune rabbit IgG. When the aliquots of RB samples labeled with ³⁵S-methionine were digested overnight with Endoglycosidase H, there was no detectable reduction of molecular weight 110-114 kD. The above findings support the belief that the retinoblastoma gene is a phosphoprotein of MW 110-114 kD. The phosphoprotein was therefore named ppRB¹¹⁰.

[0193] D. Diagnostic Procedures Utilizing Cancer Suppressing Gene Products

[0194] After locating and cloning a desired cancer suppressing gene, the cloned gene can be used to obtain a gene product useful in diagnosing for cancer related to the cancer suppressing gene.

[0195] The technique includes initially developing a product which can react with the cancer suppressing gene product of a patient's tissue sample. In this regard, the reaction between the product is observed to determine the presence or absence of the normal phenotypical expression of the cancer suppressing gene of the tissue sample.

[0196] More specifically, using the cloned cancer suppressing gene, an antibody is developed. The antibody, which is specific for the cancer suppressing gene protein product, is used to react with the cancer suppressing gene protein product in a patient's tissue sample for determining whether or not the cancer suppressing gene is functioning properly. In a typical case, proper cancer suppressing gene function is demonstrated when an immunocomplex between the antibody and the cancer suppressing gene protein product is formed. Failure of the immunocomplex is indicative of defective, abnormal or absent cancer suppressing gene protein product. Thus, failure of the antibody to form an immunocomplex with the patient tissue sample substrate is indicative of a defective or absent cancer suppressing gene in the patient.

[0197] The specific antibody is produced, in general, by utilizing the normal cancer suppressing gene protein product as an antigen according to known techniques. Other conventional techniques may also be employed for producing the desired antibodies.

[0198] As a specific example of the technique herein disclosed, the protein product of the RB gene has been identified. According to the method disclosed in pending U.S. patent application Ser. No. 098,612, immunoprecipitation of the phosphoprotein was accomplished utilizing preimmune rabbit anti-sera and, as disclosed in said application, a protein with MW 110-114 kD was immunoprecipitated with anti-ppRB¹¹⁰ IgG.

[0199] D.1 Diagnostic Procedures for Determining Cancer Predisposition

[0200] Once the cancer suppressing gene is identified and cloned, the clone is useful diagnostically. In this regard, patients can be screened for their predisposition toward cancer, by observing the phenotypical expression of a cancer suppressing gene in a tissue sample taken from a patient.

[0201] D2. Identification and Characterization of the RB Protein

[0202] As a specific example relative to the retinoblastoma cancer suppressing gene, phosphoprotein product of the retinoblastoma susceptibility gene has been located primarily in the cell nucleus having DNA binding activity. Its amino acid sequence has been identified. The phosphoprotein, identified as ppRB¹¹⁰ is utilized in diagnosing retinoblastoma and other cancers involving the retinoblastoma gene, and, to some extent, in the treatment of these cancers and in evaluating the oncogenicity of other genes.

[0203] While the identification of ppRB¹¹⁰ is summarized herein, for a complete disclosure thereof, reference may be made to the foregoing identified pending patent application Ser. No. 098,612.

[0204] As stated in pending U.S. patent application Ser. No. 098,612, experimental evidence indicates that complete inactivation of the RB gene is required for tumor formation, and that a new mode of function exists for the RB gene as a suppressing of the cancer phenotype.

[0205] Since gene action is generally intermediated by its protein product, it appears that the RB gene protein product would have a gene-regulatory activity.

[0206] Therefore, obtaining the complete amino acid sequence of the RB gene protein product, specific anti-retinoblastoma protein antibody, its biochemical characterization, subcellular localization and its DNA binding activity, are of importance for further elucidation of the RB gene regulatory and oncogenic activity.

[0207] The amino acid sequence of a protein can be determined by the genetic code of the particular gene responsible for that particular protein. Therefore, in order to isolate the protein, to determine its exact amino acid sequence and to determine its physiological function in the body, it is necessary to isolate and localize the responsible gene, to clone it and to sequence the cDNA which are useful in identification of the genes specific protein product.

[0208] Using the method of chromosomal walking from other chromosome 13 markers, retinoblastoma gene and encoding of the amino acid sequence was identified at 13 chromosome, 13 q14:11 region. By using esterase D cDNA clones and by screening the genomic and cDNA overlapping clones RB-1 and RB-2 of 1.6 kb, respectively, were identified in human cDNA libraries. Later on, another clone RB-5 was also identified.

[0209] First, the RB-1 clone was hybridized with 4.8 kb mRNA transcript in human fetal retina and placenta. In retinoblastoma samples, RB-1 clone either detected an abnormal mRNA transcript or the mRNA transcripts were not observed at all. Subsequently identified RB-5 clone, with a 3.5 kb insert, gave identical results as RB-1 in mRNA hybridization. Restriction enzyme analysis suggested that RB-5 and RB-1 clones overlapped in a 0.4 kb region and both together defined a DNA segment of about 4.6 kb, a size close to that of the normal RB mRNA transcript.

[0210] Nucleotide sequence analysis of clones RB-1 and RB-5 was performed by the dideoxy-terminator method described in Proc. Natl. Acad. Sci., 74:5463-5467 (1977) and yielded the reconstructed complete cDNA sequence. Different deletion templates were generated by the “cyclone” method in single stranded M13 phage clones, which yielded greater than 95% of the sequence. The remaining gaps were sequenced by primer extension in both strands. The complete sequence identified in this way contained 4,523 nucleotides.

[0211] Further analyses supported the belief that the RB gene product was a nucleic acid-binding protein. In addition, nucleotide sequence analysis of RB cDNA clones demonstrated a long-open reading frame encoding a hypothetical protein with features suggestive of a DNA binding function. It was identified and used as an antigen for obtaining specific antibody and to determine its predicted DNA binding.

[0212] After preparing specific rabbit polyclonal antibody against RB protein, the purified anti-RB IgG antibody was used for immunoprecipitation, immunostaining and localization of RB protein. It was believed that the antibody will be useful for diagnostic identification of RB protein in human tissue samples.

[0213] To identify the RB protein, several human cell lines known to have either normal or altered RB expression were selected.

[0214] LAN-1 neuroblastoma cell line normal human fibroblasts, human hepatoma Alexander cell line and osteosarcoma U2OS cell line were used as positive controls containing normal RB mRNA. All these cells were obtained from the American Type Culture Collection (ATCC), Inc. depository. Cell lines with expected shortened or absent RB mRNA, such as retinoblastomas cell lines Y79 (ATCC), RB355 (Gifted from Robert Philips, Toronto, Canada), WERI-1, WERI-24, and WERI-27 (Gifted from T. Sery Wills' eye hospital, Philadelphia) were used as negative controls.

[0215] All normal human cell lines as described above and all cells from five retinoblastomas were labeled with ³⁵S-methionine and immuniprecipitated with preimmune rabbit antibody IgG or rabbit anit-RB IgG.

[0216] Cells from all human cell lines were metabolically labeled with ³⁵S-methionine according to procedure described in J. Virol, 38:1064-1076 (1981). Labeled cell mixtures were immunoprecipitated with 1-20 ul, preferably 10 ul, of from 50 ug/ml-200 ug/ml, preferably 100 ug/ml of anti-RB antibody IgG using the procedure described in J. Virol, 38:1064-1076 (1981).

[0217] In all control cell lines a protein doublet with apparent molecular weight of 110-114 kD was detected. In retinoblastoma cell lines, or in cells immunoprecipitated with preimmune serum the protein doublet was not detected.

[0218] The RB proteins immunoprecipitated with rabbit anti-RB IgG were analyzed by SDS/polyacrylamide gel electrophoresis and auto-radiographed. The results indicated immunoprecipitation of the normal positive, i.e. RB protein containing cell lines labeled with ³⁵S-methionine.

[0219] D2. Localization and Function of ppRB¹¹⁰

[0220] The cells from several vertebrate species, such as QT6 (quail), NIH/3T3 (mouse), Rat-2 (Rat) and cos (monkey) were labeled with ³²P-phosphoric acid and proteins were immunoprecipitated with anti-RB IgG. Antigenically related proteins were detected in all cells with apparent similar molecular weights of 108 kD in quail, 120 kD in mouse, 128 kD in rat and 108-110 kD in monkey, as compared to 110-114 kD in human cells.

[0221] The predicted whole amino acid sequence of the ppRB¹¹⁰ protein has several characteristics similar to those appearing in other oncogenes. Therefore, the subcellular localization of the ppRB¹¹⁰ was investigated by cellular fractionization to identify the distribution of ppRB¹¹⁰ among the nuclear, cytoplasmic, or cell membrane fractions.

[0222] It was determined that 85% of ppRB¹¹⁰ was found in the nuclear fraction, while a small amount of the ppRB¹¹⁰ was located in the cell membrane. There was no detectable presence in the cytoplasmic fraction.

[0223] To further substantiate that the ppRB¹¹⁰ is localized primarily in the nucleus, the osteosarcoma cell lines U20S known to have an advantageous cell meorphology for immunohistochemical staining were used. As an experimental group, the U2OS cells were immunoprecipitated with anti-ppRB¹¹⁰ IgG. As a control group, the U2OS cells were immunoprecipitated with preimmune IgG. Both groups were then incubated with rhodamine conjugated goat anti-rabbit IgG obtained commercially from Sigma. Immunofluorescence was observed in cells reacted with anti-ppRB¹¹⁰ IgG, namely in the cell nucleus. Cells reacted with preimmune control did not show any fluorescence.

[0224] The subcellular localization of ppRB¹¹⁰ in the nuclear fraction suggests that the RB protein plays an important regulatory function in regulating other genes and has a DNA binding activity.

[0225] Certain cell lines, particularly those from tumors others than retinoblastome, such as neuroblastome LAN-1 cells were radioactively labeled with ³²P-phosphoric acid. Cellular lysates of these labeled cell mixtures were separated by single or double stranded calf thymus DNA-cellulose columns according to the method described in Mol. Cell. Biol., 6:4450-4457 (1986).

[0226] The results obtained suggest that the ppRB¹¹⁰ binds only to a limited number of DNA sites that are easily saturated. It has been previously shown that other protooncogens such as c-myc, n-myc, c-myb and c-fos are nuclear phosphoproteins with DNA binding activity Mol. Cell. Bill., 6:4450-4457 (1986), Nature, 296:262-266 (1982). Oncogenic activation of these proto-oncogenes occurs by deregulation of gene expression or by structural modification, and the gene product is essential for oncogenicity.

[0227] While radioimmunoassay techniques were utilized, it is to be understood that the methods, such as enzyme imnunoassay (Western blotting analysis), immunocytochemical assay, and others, are also suitable.

[0228] D4. Regulatory Function of ppRB¹¹⁰

[0229] It is the ppRB¹¹⁰ absence, and not its presence, that appears to be oncogenic due to the partial or complete inactivation of the RB gene. Therefore, the presence of the ppRB¹¹⁰ somehow suppresses the oncogenic activity of other genes and disallows malignant cell growth. The ppRB¹¹⁰ is thus an important regulatory protein which may prevent and inhibit, by its presence, and trigger, by its absence, the malignant growth. Thus, the importance of PPRB¹¹⁰ is in regulating other genes. The absence or loss of ppRB¹¹⁰ mediates oncogenicity.

[0230] D5. ppRB¹¹⁰ as a Diagnostic Tool

[0231] The role of ppRB¹¹⁰ as a mediator of oncogenicity leads to several practical applications.

[0232] First, the presence or absence of the ppRB¹¹⁰ serves as a diagnostic tool in determination of the presence or predisposition to the retinoblastoma and other RB genes involved tumors of the animal fetus or embryo. Thus, early diagnosis allows an early warning and treatment of retinoblastoma and other tumors with the possibility of preventing development of secondary tumorigenesis.

[0233] In practice, the use of ppRB¹¹⁰ to diagnose the presence or predisposition to retinoblastoma is through immunoscreening of the tissue biopsy with specific anti-ppRB¹¹⁰ antibody. The bioptic tissue is either radioactively labeled and immunoscreened or the proteins extracted from bioptic tissue may be blotted on nitrocellulose filter and probed with labeled antibody according to methods known in the art as Western blotting.

[0234] It is expected that such readily available diagnostic methods will be used particularly for screening families with a history of hereditary retinoblastoma. Moreover, the diagnostic method is useful also for prediction of the development of secondary cancer, such as for example osteosarcoma, fibrosarcoma, glioblastoma, breast cancer, whether or not connected with retinoblastoma.

[0235] Another use is for tumorigenesis suppression where the absent ppRB¹¹⁰ will be provided through molecular induction and gene transplanting of the RB cDNA to the individual in need of ppRB¹¹⁰.

[0236] Still another application is the suppression of cancerogenous growth by providing the intact RB gene directly to the tumor cells. The cells in turn produce ppRB¹¹⁰ which then effects the other tumorous cells.

[0237] E. Gene Therapy and Prohpylaxis

[0238] As previously described, diagnostic techniques, according to this invention, are useful in determining the susceptibility of individuals to cancer. However, in order to provide therapy and/or prophylaxis, the cloned cancer suppressing gene itself is delivered to the organism for controlling the suppression of cancer. The delivery of the cloned gene is achieved by conventional vectors, and in some applications, the cloned gene is appropriate for topical application.

[0239] The preferred delivery techniques include utilizing viruses liposimes, and other vectors. Delivery of cloned cancer suppressing genes, by means of suitable vectors, has prophylactic and/or therapeutic effects on patients having a defective or absent cancer suppressing gene while no adverse side effects would be experienced by the individual having the normal genetic complement. When a prophylactic situation is indicated, such as when a predisposition to cancer has been determined, for example by investigative diagnosis, cloned cancer suppressing genes are delivered to the patient. As indicated above, it is not expected that the administration of such cloned genes will adversely effect the individual with the ormal genetic complement.

[0240] As an example, the RB gene was tested therapeutically and prophylatically. Given the hypothetical cancer suppressing activity of the RB gene, an assay system for RB gene function was developed by introducing the gene into cultured tumor cells containing inactivated endogenous RB genes. Failure to find an effect in this simple assay would not necessarily invalidate the notion of genetic suppression of cancer. However, a positive result (suppression of the neoplastic phenotype) was realized to strongly reinforce this concept.

[0241] Direct detection of RB gene mutations would have clinical utility for the following reasons: 1) sporadic unilateral hereditary and nonhereditary cases could be distinguished by examining patients' fibroblasts, allowing accurate assessment of risk for second primary cancers and for transmission to offspring; 2) genetic diagnosis would be possible without informative RFLPs or without examining other family members. As described above, the intron 1 probe may be useful for this purpose depending on what fraction of mutant RB genes have rearrangements in this region. Other common sites of mutation in the RB gene might be identified, and probes designed specifically for their detection. It is possible that the RB gene promoter may be one such common site.

[0242] Antibodies to the RB protein may have diagnostic and/or prognostic application in clinical medicine. For example, mutations in the RB gene could be inferred by absence of immuniperoxidase staining of tumor sections, with nonneoplastic stroma providing an internal positive control. RB antibodies might be used to resolve ambiguities in tissue diagnosis of bone or soft-tissue neoplasms; Perhaps breast cancers could be usefully subclassified on the basis of RB gene involvement.

[0243] Finally, if inactivation of the RB gene is the primary cause of retinoblastoma and other cancers, then restoration of normal RB gene activity by gene transfer is a novel approach for future cancer therapy.

[0244] In order to test RB gene function at the cellular level, an assay system utilizing Rb and lux viruses was developed to introduce the gene into cultured tumor cells containing inactivated endogenous RB genes.

[0245] E1. Production of Rb and Lux Viurus Infection of Tumor Cell Lines

[0246] As an example of utilization of gene therapy, cloned RB genes were utilized in vivo and in vitro studies. In this regard, cloned RB genes were introduced into tissue cultures. As another example, cloned RB genes were delivered prophylactically to one side of a nude mouse. Subsequently, carcinogens were introduced into both sides of the nude mouse. Tumor development was observed on one side while the side which had been prophylactically treated with cloned RB genes showed no tumor development.

[0247] Production of Rb and Lux viruses. Two different anphotropic retroviruses were constructed as shown in FIG. 1. One, Rb virus, consisted of MuLV LTRs (Moloney murine RB cDNA, and neo fused to the RSV (Rous sarcoma virus) promoter (LTR-RB-RSV-Nne-LTR) Proc. Natl. Acad Sci. 80:4709 (1983). Neo encodes Tn5 neomycin phosphotransferase that confers resistance to the neomycin analog G418, and was used to select against noninfected cells J. Mol. Appl. Genet. 1:327 (1982).

[0248] The other, Lux virus, was identical except that RB was replaced by the luciferase gene Mol. Cell. Biol. 7:725 (1987). The luciferase gene served not only as a control for specific effects of the RB gene, but also as a means to examine expression efficiency of the viral construct in different cells types. These two plasmids containing proviral DNA were then transfected into PA12 cells, which carry a packaging-deficient provirus and express all the necessary components for virus production including amphotropic envelope glycoproteins Mol. Cell. Biol. 5:431 (1985) (FIG. 1B).

[0249] Since this step produced very little infectious virus, supernatants harvested from transfected PA12 cells were used to infect the ecotropic helper line psi-2 Cell 33:153 (1983); ibid 37:1053 (1984). Individual G418-resistant colonies were isolated and screened for virus production and RB protein expression. Among 10 clones screened, eight produced 10³-10⁵ G418-resistant cfu/ml when assayed with 208E rat fibroblasts as indicator cells.

[0250] Both parental clones and infected rat 208F cells expressed normal-sized human RB protein (110 kD) in addition to rodent RB protein (125 kD) when labeled with ³²P-orthophosphate and immunoprecipitated.with a polyclonal anti-RB antibody (anti-fRB) Nature 329:642 (1987). Finally, esotropic virus was used to infect PA12 cells, and a number of G418-resistant clones were screened for virus production and for expression of human RB protein. Five of 10 clones expressed RB protein, the highest titer being 4×10⁴ cfu/ml. Lux virus was obtained by an identical procedure except that colonies were screened for luciferase expression (FIG. 1B); the highest titer was 1×10⁵ cfu/ml. These two viral stocks were used for all studies described below.

[0251] Infection of tumor cell lines; expression of RB Protein. Retinoblastoma cell line WERI-Rb27 and osteosarcoma cell line Saos-2 carry inactivated RB genes, as shown by the absence of normal RB protein Nature 329:642 (1987); J-Y Shew et al. unpublished. Both cell lines had partial deletions of the RB gene Proc. Natl. Acad. Sci. 85:2210 (1988); ibid 85:6017 (1988) and are referred to as RB-cells. Another osteosarcoma cell line, U-20S, expressed normal-sized RB protein and had apparently normal RB alleles Nature 329:642 (1987). These cell lines were used as recipients for infection by RB and Lux viruses. Due to the low titer and efficiency of infection by amphotropic retrovirus, all assays included selection with G418 to remove uninfected cells. After infection with RB virus and G418 selection, RB-cell lines expressed normal-sized RB protein when labeled with ³²P-orthophosphate (FIG. 2A, lanes 2 & 4); Lux-infected RB-cells expressed no RB protein. As expected, RB protein expression in U-20S cells was not detectably altered after infection with Rb virus because of the presence of endogenous RB protein. However, G418 resistance of the selected clones indicated that viral infection had occurred.

[0252] To further verify the newly expressed RB protein in tumor cells, its cellular localization was examined. Most of the endogenous RB protein was localized to the nucleus in U-20S cells, as indicated by both cell fractionation and immunostaining. Rb virus-infected Saos-2 cells were immunostained using anti-fRB antibody. Nuclei were strongly positive for brown chromophore, reflecting RB protein location. Lux virus-infected cells were entirely unstained under the same conditions. Therefore the newly expressed RB protein was indistinguishable from native RB by three major biochemical indices (molecular weight, cellular localization and phosphorylation). RB gene expression in cells infected with Rb virus was monitored by immunoprecipitation with anti-fRB antibody before all subsequent experiments.

[0253] In order to establish that restoration of RB protein expression in RB cells influenced cell morphology and inhibited growth, the in vitro effects of RB gene expression were tested. Cultures of RB and Lux virus-infected tumor cells were compared after G418 selection as illustrated in FIG. 3. The morphology of U-20S cells, grown as a monolayer, was unchanged after infection with either virus. Monolayer culture of Saos-2 cells were unchanged by Lux virus infection, but showed obvious morphological alterations after Rb virus infection. Starting at two weeks post infection, two distinct cellular populations of G418-resistant cells were reproducibly observed. The majority of cells became flattened and greatly enlarged in average diameter (3-10 fold) compared to LUX virus-infected or uninfected cells (FIG. 3). The remaining cells were smaller and resembled uninfected parental cells. After four weeks in culture and further passaging, the larger cells were replaced by smaller cells that resembled parental or Lux virus-infected Saos-2 cells. Suspension cultures of WERI-Rb27 cells were also unchanged by Lux virus infection. Four weeks after Rb virus infection, however, moderately enlarged cells appeared that became increasingly numerous up to eight weeks. Large clumps of dead cells were also observed starting at six weeks (FIG. 3). After prolonged culture (<10 weeks), smaller cells that resembled parental or Lux virus-infected cells again became the predominat cell type.

[0254] Variation in numbers of these morphologically distinct populations suggested that the two cell types differed in rates of cell division and/or longevity in culture. This difference was quantified for monolayer osteosarcoma cells using a colony growth assay. Infected Saos-2 and U-20S cells were plated at low density, and individual colonies formed by these cells were identified (FIG. 4). The number of cells in each colony, counted under a microscope, was followed over five days. With Saos-2 cells, the majority of colonies generated by Rb-virus infected cells either grew much more slowly than colonies of Lux virus-infected cells, or stopped growing completely after a few days (FIG. 4A). However, a few fast-growing colonies were always present. Colonies of U-20S cells infected with either virus did not differ in growth rate (FIG. 4B). Subpopulations of WERI-Rb27 cells could not be separately tracked because cells grew in suspension. However, bulk population growth of WERI-Rb27 cultures was noticeably slower after Rb virus infection. These results indicate that restoration of RB protein expression in RB-cells influenced cell morphology and inhibited growth.

[0255] It was speculated that Rb virus-infected Saos-2 tumor cells that divided rapidly despite G418 selection were nonsuppressed due to a defective viral RB gene. To test this proposal, fast-growing colonies of Saos-2 cells were cloned and grown into mass cultures, and expression of the RB protein was examined by immunoprecipitation. As shown in FIG. 5, nine of nine clones had completely lost RB protein expression despite continued G418 selection. Since Rb virus-infected Saos-2 cells in early culture expressed RB protein (FIG. 1), it was reasonably deduced that small, fast-growing cells did not contain RB protein. Inactivation of the proviral RB gene was not unexpected since native or recombinant retroviruses are prone to frequent mutations or epigenetic suppression of gene expression Virol. 46:939 (1971); J. Virol. 17:74 (1976); ibid 50:42 (1984); Mol. Cell Biol. 6:1141 (1986).

[0256] Now, with further reference to the figures, FIG. 1A discloses construction of Rb virus. Plasmids p^(LLRNL) and pGem1:Rb4.7 were digested with restriction endonucleases as shown, and appropriate fragments were ligated to form pLRbRNL. Only selected restriction sites are shown (H, Hind III; C, Cla I; S, Sma I; Sc, Sea I; R, EcoR I). LTR, long terminal repeat of moloney murine leukemia virus; Lux, luciferase gene; RSV, Rous sarcoma virus promoter; Neo, Tn5 neomycin-resistance gene; Am^(r), ampicillin resistance gene; Rb, RB cDNA (4757 bp); TGA, stop condon.

[0257]FIG. 1B relates to production of amphotropic Rb and Lux viruses. Plasmids pLRbRNL or pLLRNL were transfected into amphotropic packaging cell line PA12 by calcium-phosphate precipitation. Viral supernatants were harvested after 48 hours and used to infect ecotropic packaging cell line psi-2. After 3-4 weeks of G418 selection, resistant colonies were assayed for virus production by infecting 208F rat fibroblasts. RB or Lux gene expression in G418-resistant 208F colonies was analyzed by immunoprecipitation with anti-FRB antibody for the Rb virus, or by detection of luciferase activity for the Lux virus. Virus+ and Rb+ or lux+ clones were selected as ecotropic stock lines. Viral supernatants were used to infect PA12 cells and amphotropic stock lines were isolated by repeating the process of G418 selection and analysis of neo^(r) colonies for virus production and RB or Lux gene expression.

[0258]FIGS. 2A and 2B depict expression of RB protein in Rb virus-infected retinoblastoma and osteosarcoma cell lines. In FIG. 2A, WERI=Rb27 (lanes 1 & 2), Saos-2 (lanes 3 & 4) and U-20S (lanes 5 & 6) cells were infected with Rb virus (lanes 2,4, & 6) or Lux virus (lanes 1,3,& 5) and grown in the presence of G418 (800 ug/ml for Saos-2 and U-20S and 1.0 mg/ml for WERI-Rb27) for 2 weeks (Saos-2 and U-20S) or 4 weeks (WERI-Rb27). Cells were then labeled with ³²P-phosophoric acid (0.25 mCi/ml) for three hours. Cellular lysates were immunoprecipitated with rabbi anti-fRB IgG (14) and analyzed on 7.5% SDS-polyacrylamide gels as described. RB protein (pp110^(RB)) is indicated.

[0259] In FIG. 2B, Saos-2 cells were infected with Lux virus (panel a) or Rb virus (panel b) and grown in G418-containing medium for 3 weeks in 60-mm dishes. Dishes were washed with PBS between each of the following steps: cells were fixed with 4% formaldehyde in 0.04M phosphate buffer (pH 7.4) for 20 minutes, and immersed in 1% H₂O₂ in 0.04M phosphate buffer for 10 minutes. Fixed cells were preincubated with normal goat serum for 10 minutes and then incubated with rabbit anit-fRB IgG diluted in 0.02% Triton X-100 overnight. After washing, biotinylated goat anti-rabbi IgG (TAGO, Burlingame, Calif.) was added to dishes. One hour later, cells were incubated with AB complex conjugated with horse radish peroxidase (Vector Labs, Burlingame, Calif.) for 30 minutes and then incubated with substrate (0.05% 3,3′-diaminobenzidine tetrahydrocholoride and 0.01% H₂O₂ in 0.05 M Tris-HCl, pH7.6) (Polysciences, Inc.). Reactions were stopped 3-5 minutes later by washing cells with PBS>Cells were photographed with a Nikon diaphotomicroscope.

[0260]FIG. 3 depicts morphological effects of Rb or Lux virus infection in retinoblastoma and osteosarcoma cell lines. WERI-Rb27 (a & d), Saos-2 (b & e), and U20S (c & f) cells were infected with Lux virus (a-c) or Rb virus (d-f) and cultured in G418-containing media (concentrations as in FIG. 2A) for 8 weeks (WERI-Rb27) for 4 weeks (Saos-2 and U-20S). Cells were photographed in phase contrast with a Nikon diaphotomicroscope (magnification×320 in all panels). The arrow points to an enlarged WERI-Rb27 cell while the arrowhead points to a normal-sized WERI-Rb27 cell.

[0261]FIG. 4 graphically illustrates the growth effects of Rb and Lux virus infection on retinoblastoma and osteosarcoma cells. Suspension cultures of WERI-Rb27 cells (A) were infected with Rb virus (squares) or Lux virus (circles) for 2 days and grown in the presence of G418 for 8 weeks. 1×10⁵ cells were then seeded in 200 ul of culture medium in individual wells of 96-well microtiter plates (day 0). Three wells were harvested on each of day 1 to day 5 and counted in a hemacytometer. Average cell number/well (+1 S.D.) is shown. Monolayer cultures of Saos-2 (B) and U-20S (C) cells were infected with Rb virus (squares) or lux virus (circles) for two days, then plated in 60 mm dished and grown in G418-containing medium for 7 days. Similar numbers of neomycin-resistant colonies were present in each dish; about 50 randomly selected colonies were marked and the number of cells in each colony was determined under the microscope (day 1). Numbers of cells in the same colonies were measured during the next 4 days. Average cell number/colony (+1 S.D.) is shown. In dishes with Rb virus-infected Saos-2 cells, two subpopulations of colonies were clearly distinguished, one slow-growing (n=41, filled squares) and one fast-growing (n=6, empty squares); these were plotted separately.

[0262] In FIG. 5, RB gene expression in fast-growing Saos-2 colonies infected with Rb virus is depicted. Individual fast-growing Saos-2 colonies (lanes 1-9) were isolated and grown into mass cultures in G418-containing medium. These cells and U-20S cells (lane C) were labelled with ³²P-phosphoric acid and cellular lysates were immunoprecipitated as described in relation to FIG. 2A above. RH protein (ppRB¹¹⁰) is indicated.

[0263] To test the influence of the RB protein on anchorage-independent growth, osteosarcoma cells infected with either Rb or Lux virus for their ability to grow in soft agar were assayed J. Virol. 38:1064 (1981). Different densities of cells were initially seeded and the numbers of resulting colonies were scored. As shown in Table 2, colony formation by Rb virus-infected Saos-2 cells was markedly reduced compared to uninfected or Lux virus-infected cells. In contrast, colony formation by U-20S cells did not vary significantly with regard to type of infection (Table 2). These data indicate that Saos-2 colonies formed in soft-agar could be derived from fast-growing cells. Therefore, anchorage-independent growth was retarded by exogenous RB protein in osteosarcoma cells lacking endogenous RB protein. TABLE 2 Soft-agar colony formation of Rb or Lux virus-infected osteosarcoma cells. Colony number of Saos-2 U-20S cell number seeded — Lux Rb — Lux Rb 1.0 × 10⁵ TMTC 396 56 384 340 290 2.5 × 10⁴ 124 138 7 109 151 90 # 0.35% soft agar as described (24). Total colony numbers were scored after 20 days of growth. Individual colonies of Saos-2 contained more than 50 cells, whereas U-20S contained about 30 cells. TMTC: Too many to count.

[0264] An important experimental test of neoplastic behavior is the ability of injected cells to form tumors in nude mice. Conversely, loss of tumorigenicity is the most important validation for suppression of the neoplastic phenotype by the RB gene. WERI-Rb27 was considered a good candidate for the tumorigenicity assay, since it consistently formed tumors in nude mice three weeks after injection of 1-2×10⁷ cells (Table 3).

[0265] On the other hand, Saos-2 and U-20S were only poorly tumorigenic. Two experiments were performed with WERI-Rb27 cells, one at three weeks and one at five weeks post infection with each virus in which 2×10⁷ viable infected WERI-Rb27 cells were injected into the flanks of nude mice; right flanks was used for Rb virus-infected cells, and left flanks of the same mice were used as controls with LUX virus-infected tumor cells. Seven of seven mice formed tumors only on the left side (from Lux virus-infected cells), whereas zero of seven formed tumors on the right side (from Rb virus-infected cells) followed bilateral injections of WERI-Rb27 cells infected as above (Table 3). Thus exogenous RB protein demonstrably suppressed tumor formation in one highly tumorigenic retinoblastoma cell line. Rb virus infection severely retarded the growth rate of Saos-2 cultures, so it was impossible to accumulate sufficient numbers of infected cells for our assay.

[0266] These in vitro and in vivo results support the conclusion that replacement of the RB-tumor cells suppressed their neoplastic behavior, while tumor cells with apparently normal RB genes were not so affected. TABLE 3 Tumorigenicity of RB or Lux virus-infected WERI - RB27 cells. No. of Mice with tumor / No. of mice injected Experiment # Parental Lux Rb 1 5/5 5/5 0/5 2 — 2/2 0/2 # (experiment 2). Cell viability was verified by trypan-blue exclusion, and 2 × 10⁷ viable virus-infected # cells were injected subcutaneously into either flank of the same nude-mouse. The same number of uninfected parental # cells were injected into other mice. Tumor formation was scored after two months as presence or absence of a palpable # tumor mass.

[0267] E6. Use of the RB Gene in Cancer Suppression

[0268] Since two different meanings are attached to the term “cancer suppression”, the following distinction may be drawn. Detection of inactivating mutations of the RB gene in natural human tumors supports the idea that the RB gene normally functions to “suppress” or “prevent” tumor formation in susceptible precursor cells. However, this does not necessarily imply that replacement of this gene would “suppress” or “revert” neoplastic cells to more normal behavior later in their evolution. For example, failure of the RB gene to suppress RB-tumor cells might be due to the acquisition of multiple additional alterations during oncogenesis. To test these possibilities, interventional experiments were conducted. In this initial study, a normal RB gene was introduced by viral mediated gene transfer into cultured human tumor cells that lacked endogenous RB protein. Suppression of the neoplastic phenotype was observed both by in vitro indices, such as soft agar colony formation, and by an in vivo assay, that of tumorigenicity in nude mice. Therefore, the cloned retinoblastoma gene indeed satisfied one definition of a human cancer suppressing gene: it functioned to suppress neoplastic behavior of certain tumor cells. As expected, no suppression effects of exogenous RB protein were observed in tumor cells that contained an intact endogenous RB gene.

[0269] Tests have established that the RB gene has a role in the suppressing of multiple types of human cancer. The RB gene was initially defined as the genetic element conferring susceptibility to hereditary retinoblastoma. Children surviving this form of retinoblastoma were highly predisposed to second primary tumors later in life, suggesting a broader role for the RB gene in other cancers J. Cell. Biochem. in press (1988). Mutations of the RB gene are often detected in retinoblastoma tumors; the most sensitive indicator is absence of RB protein, which has been observed in all retinoblastomas tested to date Nature 329:642 (1987). Using similar techniques, complete inactivation of the RB gene has also been found in a wide variety of nonretinoblastoma tumors such as osteosarcoma, synovial sarcoma and other soft tissue sarcomas, breast carcinoma and small cell lung carcinoma Cancer Res. 48:3939 (1988); Hum. Pathol. 19:487 (1988); Proc. Natl. Acad. Sci. 84:9059 (1987); Science 241:218 (1988); ibid 241:353 (1988); J. Y. Shaw et al. unpublished. Thus, it has been demonstrated that a normal RB gene has cancer suppression activity not only in retinoblastoma cells but also in RB-osteosarcoma cells; similar effects have been observed in RB-breast cancer cells (E. Y.-H. P. Lee & W.-H. Lee, unpublished). In conjunction with observations of RB mutations in natural human tumors, these results support the conclusion that loss of this gene is a critical step, perhaps the initial step, in the genesis of several kinds of human cancer.

[0270] Pending U.S. patent application Ser. No. 108,748 discloses and claims the RB gene and its clone. The RB gene and its clone had the nucleotide sequence depicted in Table 2. TABLE 4 TTCCGGTTTT TCTCAGGGGA CGTTGAAATT ATTTTTGTAA CGGGAGTCGG GAGAGGACGG 60 GGCGTGCCCC GCGTGCGCGC GCGTCGTCCT CCCCGGCGCT CCTCCACAGC TCGCTGGCTC 120 CCGCCGCGGA AAGGCGTC ATG CCG CCC AAA ACC CCC CGA AAA ACG GCC GCC 171                     Met Pro Pro Lys Thr Pro Arg Lys Thr Ala Ala                         1                5                  10     ACC GCC GCC GCT GCC GCC GCG GAA CCC CCG GCA CCG CCG CCG CCG CCC 219 Thr Ala Ala Ala Ala Ala Ala Glu Pro Pro Ala Pro Pro Pro Pro Pro              15                  20                  25 CCT CCG TAG GAG GAC CCA GAG CAG GAC AGC GGC CCG GAG GAC CTG CCT 267 Pro Pro Glu Glu Asp Pro Glu Gln Asp Ser Gly Pro Glu Asp Leu Pro          30                  35                  40 CTC GTC AGG CTT GAG TTT GAA GAA ACA GAA GAA CCT GAT TTT ACT GCA 315 Leu Val Arg Leu Glu Phe Glu Glu Thr Glu Glu Pro Asp Phe Thr Ala      45                  50                 55 TTA TGT CAG AAA TTA AAG ATA CCA GAT CAT GTC AGA GAG AGA GCT TGG 363 Leu Cys Gln Lys Leu Lys Ile Pro Asp His Val Arg Glu Arg Ala Trp  60                  65                  70                  75 TTA ACT TGG GAG AAA GTT TCA TCT GTG GAT GGA GTA TTG GGA GGT TAT 411 Leu Thr Trp Glu Lys Val Ser Ser Val Asp Gly Val Leu Gly Gly Tyr                  80                  85                  90 ATT CAA AAG AAA AAG GAA CTG TGG GGA ATC TGT ATC TTT ATT GCA GCA 459 Ile Gln Lys Lys Lys Glu Leu Trp Gly Ile Cys Ile Phe Ile Ala Ala              95                 100                 105 GTT GAC CTA GAT GAG ATG TCG TTC ACT TTT ACT GAG CTA CAG AAA AAC 507 Val Asp Leu Asp Glu Met Ser Phe Thr Phe Thr Glu Leu Gln Lys Asn         110                 115                  120 ATA GAA ATC AGT GTC CAT AAA TTC TTT AAC TTA CTA AAA GAA ATT GAT 555 Ile Glu Ile Ser Val His Lys Phe Phe Asn Leu Leu Lys Glu Ile Asp     125                 130                 135 ACC AGT ACC AAA GTT GAT AAT GCT ATG TCA AGA CTG TTG AAG AAG TAT 603 Thr Ser Thr Lys Val Asp Asn Ala Met Ser Arg Leu Leu Lys Lys Tyr 140                 145                 150                 155 GAT GTA TTG TTT GCA CTC TTC AGC AAA TTG GAA AGG ACA TGT GAA CTT 651 Asp Val Leu Phe Ala Leu Phe Ser Lys Leu Glu Arg Thr Cys Glu Leu                 160                 165                 170 ATA TAT TTG ACA CAA CCC AGC AGT TCG ATA TCT ACT GAA ATA AAT TCT 699 Ile Tyr Leu Thr Gln Pro Ser Ser Ser Ile Ser Thr Glu Ile Asn Ser             175                 180                 185 GCA TTG GTG CTA AAA GTT TCT TGG ATC ACA TTT TTA TTA GCT AAA GGG 747 Ala Leu Val Leu Lys Val Ser Trp Ile Thr Phe Leu Leu Ala Lys Gly         190                 195                 200 GAA GTA TTA CPA ATG GAA GAT GAT CTG GTG ATT TCA TTT CAG TTA ATG 795 Glu Val Leu Gln Met Glu Asp Asp Leu Val Ile Ser Phe Gln Leu Met     205                   210                    215                  CTA TGT GTC CTT GAC TAT TTT ATT AAA CTC TCA CCT CCC ATG TTG CTC 843 Leu Cys Val Leu Asp Tyr Phe Ile Lys Leu Ser Pro Pro Met Leu Leu 220                  225                  230               235 AAA GAA CCA TAT AAA ACA GCT GTT ATA CCC ATT AAT GGT TCA CCT CGA 89l Lys Glu Pro Tyr Lys Thr Ala Val Ile Pro Ile Asn Gly Ser Pro Arg                   240                    245                250 ACA CCC AGG CGA GGT CAG AAC AGG AGT GCA CGG ATA GCA AAA CAA CTA 939 Thr Pro Arg Arg Gly Gln Asn Arg Ser Ala Arg Ile Ala Lys Gln Leu             255                  260                   265            GAA AAT GAT ACA AGA ATT ATT GAA GTT CTC TGT AAA GAA CAT GAA TGT 987 Glu Asn Asp Thr Arg Ile Ile Glu Val Leu Cys Lys Glu His Glu Cys         270                  275                  280             AAT ATA GAT GAG GTG AAA AAT GTT TAT TTC AAA AAT TTT ATA CCT TTT 1035 Asn Ile Asp Glu Val Lys Asn Val Tyr Phe Lys Asn Phe Ile Pro Phe     285                  290                   295                   ATG AAT TCT CTT GGA CTT GTA ACA TCT AAT GGA CTT CCA GAG GTT GAA 1083 Met Asn Ser Leu Gly Leu Val Thr Ser Asn Gly Leu Pro Glu Val Glu 300                 305                  310                315 AAT CTT TCT AAA CGA TAC GAA GAA ATT TAT CTT AAA AAT AAA GAT CTA 1131 Asn Leu Ser Lys Arg Tyr Glu Glu Ile Tyr Leu Lys Asn Lys Asp Leu                  320                     325            330 GAT GCA AGA TTA TTT TTG GAT CAT GAT AAA ACT CTT CAG ACT GAT TCT 1179 Asp Ala Arg Leu Ahe Leu Asp His Asp Lys Thr Leu Gln Thr Asp Ser              335                    340                    345          ATA GAC AGT TTT GAA ACA CAG AGA ACA CCA COA AAA AGT AAC CTT GAT 1227 Ile Asp Ser Ahe Glu Thr Gln Arg Thr Pro Arg Lys Ser Asn Leu Asp         350                   355                   360                 GAA GAG GTG AAT GTA ATT CCT CCA CAC ACT CCA GTT AGG ACT GTT ATG 1275 Glu Glu Val Asn Val Ile Pro Pro His Thr Pro Val Arg Thr Val Met     365                    370                    375                  AAC ACT ATC CAA CAA TTA ATG ATG ATT TTA AAT TCA GCA AGT GAT CAA 1323 Asn Thr Ile Gln Gln Leu Met Met Ile Leu Asn Ser Ala Ser Asp Gln 380                   385                     390                  395 CCT TCA GAA AAT CTG ATT TCC TAT TTT AAC AAC TGC ACA GTG AAT CCA 1371 Aro Ser Glu Asn Leu Ile Ser Tyr Phe Asn Asn Cys Thr Val Asn Pro                   400                    405             410 AAA GAA AGT ATA CTG AAA AGA GTG AAG GAT ATA GGA TAC ATC TTT AAA 1419 Lys Glu Ser Ile Leu Lys Arg Val Lys Asp Ile Gly Tyr Ile Phe Lys             415                     420                  425        GAG AAA TTT GCT AAA GCT GTG GGA CAG GGT TGT GTC GAA ATT GGA TCA 1467 Glu Lys Ahe Ala Lys Ala Val Gly Gln Gly Cys Val Glu Ile Gly Ser         430                      435                     440                  CAG CGA TAC AAA CTT GGA GTT CGC TTG TAT TAC CGA GTA ATG GAA TCC 1515 Gln Arg Tyr Lys Leu Gly Val Arg Leu Tyr Tyr Arg Val Met Glu Ser    445                    450                  455                   ATG CTT AAA TCA GAA GAA GAA CGA TTA TCC ATT CAA AAT TTT AGC AAA 1563 Met Leu Lys Ser Glu Glu Glu Arg Leu Ser Ile Gln Asn Phe Ser Lys 460                   465                    470           475 CTT CTG AAT GAC AAC ATT TTT CAT ATG TCT TTA TTG GCG TGC GCT CTT 1611 Leu Leu Asn Asp Asn Ile Ahe His Met Ser Leu Leu Ala Cys Ala Leu                  480                    485              490 GAG GTT GTA ATG GCC ACA TAT AGC AGA AGT ACA TCT CAG AAT CTT GAT 1659 Glu Val Val Met Ala Thr Tyr Ser Arg Ser Thr Ser Gln Asn Leu Asp                 495                   500       505 TCT GGA ACA GAT TTG TCT TTC CCA TGG ATT CTG AAT GTG CTT AAT TTA 1707 Ser Gly Thr Asp Leu Ser Phe Pro Trp Ile Leu Asn Val Leu Asn Leu         510                515                   520                  AAA GCC TTT GAT TTT TAC AAA GTG ATC GAA AGT TTT ATC AAA GCA GAA 1755 Lys Ala Phe Asp Phe Tyr Lys Val Ile Glu Ser Phe Ile Lys Ala Glu     525                   530                    535                  GGC AAC TTG ACA AGA GAA ATG ATA AAA CAT TTA GAA CGA TGT GAA CAT 1803 Gly Asn Leu Thr Arg Glu Met Ile Lys His Leu Glu Arg Cys Glu His 540                    545                   550                   555 CGA ATC ATG GAA TCC CTT GCA TGG CTC TCA GAT TCA CCT TTA TTT GAT 1851 Arg Ile Met Glu Ser Leu Ala Trp Leu Ser Asp Ser Pro Leu Phe Asp                  560                  565                 570     CTT ATT AAA CAA TCA AAG GAC CGA GAA GGA CCA ACT GAT CAC CTT GAA 1899 Leu Ile Lys Gln Ser Lys Asp Arg Glu Gly Pro Thr Asp His Leu Glu                575                580                  585         TCT GCT TGT CCT CTT AAT CTT CCT CTC CAG AAT AAT CAC ACT GCA GCA 1947 Ser Ala Cys Pro Leu Asn Leu Pro Leu Gln Asn Asn His Thr Ala Ala         590                595                 600                GAT ATG TAT CTT TCT CCT GTA AGA TCT CCA AAG AAA AAA GGT TCA ACT 1995 Asp Met Tyr Leu Ser Pro Val Arg Ser Pro Lys Lys Lys Gly Ser Thr     605                    610                  615                 ACG CGT GTA AAT TCT ACT GCA AAT GCA GAG ACA CAA GCA ACC TCA GCC 2043 Thr Arg Val Asn Ser Thr Ala Asn Ala Glu Thr Gln Ala Thr Ser Ala 620                  625                   630              635 TTC CAG ACC CAG AAG CCA TTG AAA TCT ACC TCT CTT TCA CTG TTT TAT 2091 Phe Gln Thr Gln Lys Pro Leu Lys Ser Thr Ser Leu Ser Leu Phe Tyr                  640                 645                    650 AAA AAA GTG TAT CGG CTA GCC TAT CTC CGG GTA AAT ACA CTT TGT GAA 2139 Lys Lys Val Tyr Arg Leu Ala Tyr Leu Arg Leu Asn Thr Leu Cys Glu                655                660                   665         CGC CTT CTG TCT GAG CAC CCA GAA TTA GAA CAT ATC ATC TGG ACC CTT 2187 Arg Leu Leu Ser Glu His Aro Glu Leu Glu His Ile Ile Trp Thr Leu         670                 675               680                 TTC CAG CAC ACC CTG CAG AAT GAG TAT GAA CTC ATG AGA GAC AGG CAT 2235 Phe Gln His Thr Leu Gln Asn Glu Tyr Glu Leu Met Arg Asp Arg His     685                  690                695                 TTG GAC CAA ATT ATG ATG TGT TCC ATG TAT GGC ATA TGC AAA GTG AAG 2283 Leu Asp Gln Ile Met Met Cys Ser Met Tyr Gly Ile Cys Lys Val Lys 700                 705                 710                 715 AAT ATA GAC CTT AAA TTC AAA ATC ATT GTA ACA GCA TAC AAG GAT CTT 2331 Asn Ile Asp Leu Lys Phe Lys Ile Ile Val Thr Ala Tyr Lys Asp Leu                  720                  725                 730     CCT CAT GCT GTT CAG GAG ACA TTC AAA CGT GTT TTG ATC AAA GAA GAG 2379 Pro His Ala Val Gln Glu Thr Phe Lys Arg Val Leu Ile Lys Glu Glu                   735                  740                 745         GAG TAT GAT TCT ATT ATA GTA TTC TAT AAC TCG GTC TTC ATG CAG AGA 2427 Glu Tyr Asp Ser Ile Ile Val Phe Tyr Asn Ser Val Ahe Met Gln Arg         750                  755                 760                CTG AAA ACA AAT ATT TTG CAG TAT GCT TCC ACC AGG CCC CCT ACC TTG 2475 Leu Lys Thr Asn Ile Leu Gln Tyr Ala Ser Thr Arg Pro Pro Thr Leu     765                  770                  775                 TCA CCA ATA CCT CAC ATT CCT CGA AGC CCT TAC AAG TTT CCT AGT TCA 2523 Ser Pro Ile Pro His Ile Pro Arg Ser Pro Tyr Lys Phe Pro Ser Ser 780                 785                   790               795 CCC TTA CGG ATT CCT GGA GGG AAC ATC TAT ATT TCA CCC CTG AAG AGT 2571 Pro Leu Arg Ile Pro Gly Gly Asn Ile Tyr Ile Ser Pro Leu Lys Ser                 800                 805                 810     CCA TAT AAA ATT TCA GAA GGT CTG CCA ACA CCA ACA AAA ATG ACT CCA 2619 Aro Tyr Lys Ile Ser Glu Gly Leu Pro Thr Pro Thr Lys Met Thr Pro                    815                820                 825         AGA TCA AGA ATC TTA GTA TCA ATT GGT GAA TCA TTC GGG ACT TCT GAG 2667 Arg Ser Arg Ile Leu Val Ser Ile Gly Glu Ser Phe Gly Thr Ser Glu         830                   835                  840               AAG TTC CAG AAA ATA AAT CAG ATG GTA TGT AAC AGC GAC CGT GTG CTC 2715 Lys Ahe Gln Lys Ile Asn Gln Met Val Cys Asn Ser Asp Arg Val Leu      845                    850                 855                AAA AGA AGT GCT GAA GGA AGC AAC CCT CCT AAA CCA CTG AAA AAA CTA 2763 Lys Arg Ser Ala Glu Gly Ser Asn Pro Pro Lys Aro Leu Lys Lys Leu 860                 865                870                   875 CGC TTT GAT ATT GAA GGA TCA GAT GAA GCA GAT GGA AGT AAA CAT CTC 2811 Arg Phe Asp Ile Glu Gly Ser Asp Glu Ala Asp Gly Ser Lys His Leu                     880                  885            890 CCA GGA GAG TCC AAA TTT CAG CAG AAA CTG GCA GAA ATG ACT TCT ACT 2859 Pro Gly Glu Ser Lys Phe Gln Gln Lys Leu Ala Glu Met Thr Ser Thr                   895                   900                 905         CGA ACA CGA ATG CAA AAG CAG AAA ATG AAT GAT AGC ATG GAT ACC TCA 2907 Arg Thr Arg Met Gln Lys Gln Lys Met Asn Asp Ser Met Asp Thr Ser               910                 915                920                AAC AAG GAA GAG AAA TGAGGATCTC AGGACCTTGG TGGACACTGT GTACACCTCT 2962 Asn Lys Glu Glu Lys     925 GGATTCATTG TCTCTCACAG ATGTGACTGT AT 2994

[0271] E3. Suppression of Oncogenicity in vitro and in vivo by the RB Gene

[0272] (a) Expression vectors containing functional RB cDNA clones were prepared as follows: A full-length 4.7 kb RB cDNA was constructed from three overlapping cDNA sequences, RB-1, RB-5, and Y79RB. This cDNA is placed under the control of either SV40 early gene promotor or LTR of Moloney murine leukemia virus and is inserted into a retroviral vector (MuLV-LTR-neo).

[0273] (b) Production of RB-virus: Infectious viruses containing RB genes are made from packaging cell lines 2 after viral DNA-calcium phosphate coprecipitation in the presence of polybene. Forty eight hours later, the supernatant containing ecotropic RB-neo virus is harvested and used to infect pA12 cells, which is another helper line providing amphotropic envelop protein. While only a small fraction of pA12 cells are infected with ecotropic RB-neo virus, the positively infected pA12 cells are enriched under the G418 selection for the neo-resistant phenotype. Viral particles released from infected pA12 cells are pseudotypic with amphotropic envelop proteins and are able to infect species beside rodents. The virus can be checked for the presence of the RB gene by either hybridizing with RB probe or by its ability to express RB proteins.

[0274] (c) Phenotypic changes of retinoblastoma cells by RB gene: Several lines of retinoblastoma cells, such as Y79 or WERI-1, can produce palpable tumors in nude mice within 4 weeks. These cells were infected with infectious virus containing the functional RB gene and then assayed for their tumorigenicity. Meanwhile, the expression of RB gen in these infected cells was checked. LTR-neo virus carrying only neo genes were used as control. In addition, the infectious RB-virus was directly inoculated into established retinoblastoma tumors in nude mice and the suppression of tumor growth examined.

[0275] E4. Transformation by Inactivation of RB Genes

[0276] (a) Infectious virus containing defective RB sequences were constructed similar to the procedures described above and used for targeted mutagenesis of the endogenous RB gene.

[0277] (b) Fibroblasts from retinoblastoma patients, such as GM 1142 and S-362, contained only a single copy of the functional RB gene and were used as target cells for the inactivation of RB gene by homologous recombination. Colonies resistant to G418 are characterized according to the following parameters: (1) insertion site; (2) expression of RB proteins; and (3) transforming phenotype both in vivo and in vitro.

[0278] A view of the cancer suppressing characteristics of the RB gene, the use of the gene or its clone as a pharmaceutical has been established. In addition, the RB gene may be used for prophylactic prenatal and postnatal screening, and for prediction of the development of secondary cancer, such as osteosarcoma, fibrosarcoma, glioblastoma, breast cancer, and others, whether or not connected with retinoblastoma.

[0279] It will be recognized that another use is the suppression of cancer growth by providing RB gene cDNA directly to the tumor cells, which cells in turn will product ppRB¹¹⁰ which will effect the other tumorous cells.

[0280] Although diagnostic and prophylactic methods with regard to the RB gene have been described, it must be understood that the present invention is intended to cover the use of any replacement gene as a pharmaceutical to treat animals, including humans, who have a cancerous condition or who have inactive, mutated or defective cancer suppressing genes. Injecting, treating, or by other appropriate means, the animal having a defective gene with its identical or nearly identical natural or cloned non-defective gene or gene fragment to treat and/or prevent cancer is what is intended by this invention.

[0281] F. Animal Models for Evaluating Suspected Environmental Influence Carcinogenicity

[0282] In order to determine carcinogenicity of suspected environmental influences, the cancer suppressing gen of an animal model is controlled by genetic manipulation to render it susceptible to carcinogenic influences. In this regard, one of a pair of cancer suppressing genes of the animal is rendered inactive, so that the offspring of the animal may be exposed to the expected environmental carcinogen for testing purposes.

[0283] Tumor development of the animal thus exposed is a positive indication of carcinogenicity of the suspected environmental influence.

[0284] As an example of production of a mouse model for evaluation of carcinogenicity of suspected environmental influences, a strain of mice had been developed having heterogenicity of the RB gene. Exposure of the mouse to a carcinogen results in alteration of the dominant RB gene thereby resulting in production of the homozygous, recessive condition with attendant tumor development.

[0285] Understanding the molecular basis for transforming a normal cell into a tumor cell is a major challenge for scientists studying tumorigenesis. For many experimental tumors, multiple stages of carcinogenesis have been demonstrated Nature, 315:190, (1985). Recent studies have shown that activations of oncogenes might be involved in the initiation of carcinogenesis, and multiple oncogenes might be required in the process of immortalization of normal cells and the expression of transforming phenotype Nature 304:596, (1983). Generally, these oncogenes are dominantly acting genes and the expressions of these genes products in excess quantity or in altered form are necessary for malignant transformation.

[0286] A major paradox in cancer biology arises from studies with cell hybridization between normal and malignant cells. It has been shown that the tumorigenic activity of malignant cells can be suppressed by genes or chromosomes from normal cells and the malignancy of the hybrid cell reverts after loss of DNA from normal cells. Adv. Cancer Res., 44:43, (1985). This suggest that tumorigenicity is recessive in nature and inactivation of these “tumor suppressing genes” may also be involved in the initiation of human tumorigenesis Science, 238:1539, (1987).

[0287] Karyotypic examination of somatic cells (fibroblasts) from patients with hereditary retinoblastoma has shown visible deletions of the long arms of chromosome 13 in some cases Birth Defects, 12:131, (1976). Similar defections were observed in retinoblastoma tumor cells Cancer Genet. Cytogenet. 6:213, (1982). Band q14 was common among all deletions and presumably contains a hypothetical gene (RB) determining the susceptibility to hereditary retinoblastoma. Based on the clinical observation, it has been suggested that initiation of tumorigenesis can result from as few as two mutation events and that retinoblastoma arises by the loss of both alleles at the same locus Proc. Natl. Acad. Sci. U.S.A., 68:820, (1971); Cancer, 35:1022, (1975). Consequently, the presence of the hypothetical gene product would prohibit or suppress tumorigenesis while loss of the gene function will result in malignant growth.

[0288] A gene on chromosome 13 has been identified as the RB gene Science, 235:1394, (1987); Nature, 323:643, (1986). It encoded a 4.7 kb mRNA transcript, expressed in most normal cells including fetal retina. Partial or complete deletion of this gene were detected in 2 of 6 retinoblastomas examined while 4 had apparently intact genes. However, the RB mRNA was altered in 6 of 6 retinoblastomas examined and the changes included either expression of shortened mRNA message (4.0 kb instead of 4.7 kb) or absent expression. Complete loss of RB gene function in retinoblastomas was further confirmed at the level of protein translation Nature, 329:642, (1987).

[0289] Antibody raised against a segment of the RB gene product can immunoprecipitate a protein of 110 kd in normal cells and many non-retinoblastoma tumor cells. However, this 110 kd protein was absent in 5 of 5 retinoblastomas examined. This suggests its importance in the oncogenesis of retinoblastoma. Furthermore, this protein was found to be a phosphoprotein with DNA binding activity and located in the nucleus thereby suggesting its regulatory roles in the expression of genes. As discussed above, the phosphoprotein has been identified as ppRB¹¹⁰.

[0290] Further genetic identification of the RB gene can be confirmed by its expected biological functions. Two basic questions can be addressed: 1) Whether oncogenicity of retinoblastoma cells is suppressed by the presence of functional RB gene products; and 2) Whether the absence of the functional RB gene results in the malignant phenotype. Introduction of chromosome 11 into Wilm's tumor cells resulted in the suppression of tumorigenicity in nude mice although these cells remained morphologically transformed in tissue culture Science, 236:175, (1987).

[0291] Of interest, also, is whether the single RB gene can suppress the tumorigenicity of retinoblastoma cells. Targeted mutagenesis by homologous recombination has been used successfully in inactivation of the myosin heavy chain gene in Dictyosteliym discoideum Science, 236:1086, (1987). Targeted mutagenesis with homologous recombination has also been shown in diploid cells as well as mouse embryonic stem cells Cell, 44:419, (1986); Cell, 51:503, (1987). Therefore, inactivation of the RB gene by targeted mutagenesis provides important information about its role in the regulation of cell growth and its oncogenic potential. In addition, the roles of the RB gene in the oncogenesis of second primary tumors in retinoblastoma patients can be studied by these methods.

[0292] In order to study RB gene function, an animal model was prepared. Two potential animal models for Lesch-Nyhan syndrome have been developed. Nature, 326:292, (1987). Nature, 326:295, (1987) Both mouse model systems were derived by construction of chimeric mice with HPRT-mutagenized mouse embryonic carcinoma (EC) or embryonic stem (ES) cells which can give rise to germ cells in chimeras. These chimeras allow the derivation of strains of mutant mice having the same biochemical defect as Lesch-Nyhan patients. The objective was to utilize either mouse ES or EC cells to establish chimeric mice with one inactive allele of the RB gene.

[0293] Either mouse ES or EC cells were used to establish chimeric mice with one inactive allele of RB gene for studying its biological significance. One allele of the RB gene of the mouse ES cell (rb/rb) was inactivated by targeted mutagenesis with a viral vector containing defective RB sequences. Another selection marker, which aligns in frame with the RB gene but is inactive in defective RB-virus, was incorporated for selection purposes.

[0294] After homologous recombination with endogenous RB, the marker expressed under the control of endogenous RB regulatory sequence and was selected along with neo-resistancy. The neomycin-resistant ES cell were further examined for the rb/-) genotype by DNA hybridization with RB probe and were injected into mouse blastocyctes to construct chimeric animals Proc. Natl. Acad. Sci. U.S.A., 83:9065, (1986).

[0295] The resulting chimeric mice are bred to maintain a colony before sacrificing and examination for the (rb/-) phenotype of the primary fibroblast.

[0296] The invention of the animal model for studying cancer suppressing gene function is now presented in greater detail. Two potential animal models for Lesch-Nyhan syndrome were developed. Both mouse model systems were derived by construction of chimeric mice with HPRT-mutagenized mouse embryonic carcinoma (EC) or embryonic stem (ES) cells which can give rise to germ cells in chimeras. These allow the derivation of strains of mutant mice having the same biochemical defect as seen in Lesch-Nyhan patients. In the present invention, mouse ES cells were used as the target for RB gene inactivation via homologous recombination.

[0297] The expressions of the RB gene in different tissues of the mouse were examined by either Northern blotting of the poly(A) RNAs with mouse DNA probes or immunoprecipitation of mouse RB proteins with RB specific antibody. The expression of RB gene in ES cells as well as fetal retinal cells were the main targets of investigation.

[0298] One allele of the RB genes of the mouse ES CELL (rb/rb) was inactivated by targeted mutagenesis with DNA fragments containing defective RB sequences. Previously, the mouse RB cDNA has been isolated using the human RB cDNA as probe. Several mouse genomic DNA clones were isolated from a mouse genomic library by screening with mouse cDNA probe. These mouse genomic clones were used to construct the DNA fragment containing an inactivated RB coding sequence.

[0299] Basically, a neomycin resistant gene derived from Tn5 was inserted into mouse genomic DNA fragments of 5.6 and 10 Kb with neomycin and/or G418 used for selection. In general, two types of vectors may be used for the targeted mutagenesis, based on the mode of action of homologous recombination. The first is a replacement vector carrying homologous sequences of the same orientation at each end of the vector and which results in an exact copy of the gene with internal neo^(r) gene. The other is an insertional vector carrying homologous sequences of opposite orientation at each ends of the vector. However, the original DNA reading frame will be continued if this DNA fragment is circlized. When this vector was inserted into the exact position of the endogenous RB gene, an internal duplication of part of the RB was established, and thus, inactive RB gene was produced. Both types of vectors were constructed and the inactivation of RB genes in ES cells was accomplished by both approaches.

[0300] It was found that the vectors introduced into the ES cells either randomly integrate into the chromosome or specifically integrate into the RB loci. This fact creates difficulty for the selection of exact homologous recombinants or for simple neomycin resistant phenotype selection. Thus, another selection marker was incorporated for selection purposes.

[0301] Studies have shown that incorporation of herpes simplex viral tk gene into the targeted mutagenesis vector described above was beneficial. Basically, the HSV tk gene was linked to the end of a linealized vector. If the random integration of the tk-vector occurred, the tk gene would be carried over into the integration site. However, site specific homologous recombination can only occur after loss of the terminal tk sequence.

[0302] Recent development of compounds, such as acyclovir and ganciclovir, has provided an excellent selection system for cells with or without the tk gene Antimicrob. and Chemother., 31:844-949 (1987). Therefore, ES cells with neo(+) and tk(−) were selected out by addition of G418 and ganciclovir respectively. Vectors with and/or without tk gene were both used to test their targeted mutagenesis efficiency. The neomycin-resistant ES cell was further examined for (rb/-) genotype by DNA hybridization with an RB probe.

[0303] Mouse ES cells thus mutated were screened for the detection of one inactive RB allele and one active allele of RB gene by RFLP analysis as well ploymerase chain reaction analysis. RB(±) ES cells obtained were reintroduced by microinjection into blastocysts (early embryo) obtained from superovulated female mice. The blastocysts carrying the RB (±) ES cells were then transplanted back to the uterus of a pseudopregnant female mouse Proc. Natl. Acad Sci U.S.A. 83:9065, (1986). After the foster mother mouse gave birth, the offspring were examined for the hereditary transmission of the mutationally inactivated RB allele.

[0304] The animal models developed according to the present invention are useful for the evaluation of suspected carcinogenicity of environmental substances. Because tumorigenicity is observed only when at least one of the cancer suppressing genes at a given locus is defective, mutated or missing, tumor development in the animal after exposure to the environmental substance is a positive indication of carcinogenicity for the substance.

[0305] In addition to their value in testing for substance carcinogenicity, the chimeric animal is useful for evaluating the pharmaceutical effect of the RB gene and RB gene products. It has been found that the administration of the RB gene and/or RB gene products to the healthy cell has no discernible adverse side effects. Thus, the RB gene and/or its products can be administered to organisms to correct a genetic deficiency while the risk of undesirable reactions has been reduced.

[0306] As used in this specification, the terms “defective” and “inactive” when referring to a gene, are intended to mean the condition wherein the gene expresses an abnormal phenotype or no phenotype.

[0307] While particular embodiments of the present invention have been disclosed, it is to be understood that various different modifications are possible and are contemplated within the true spirit and scope of the appended claims. There is no intention, therefore, of limitations to the exact abstract or disclosure herein presented.

1 2 2994 base pairs nucleic acid single linear DNA (genomic) CDS 139..2922 /product= “RB protein” /note= “retinoblastoma (RB) gene” - 1273..2922 /note= “truncated RB protein fragment p56-RB” - 2887..2922 /note= “RB protein C-terminal peptide” 1 TTCCGGTTTT TCTCAGGGGA CGTTGAAATT ATTTTTGTAA CGGGAGTCGG GAGAGGACGG 60 GGCGTGCCCC GCGTGCGCGC GCGTCGTCCT CCCCGGCGCT CCTCCACAGC TCGCTGGCTC 120 CCGCCGCGGA AAGGCGTC ATG CCG CCC AAA ACC CCC CGA AAA ACG GCC GCC 171 Met Pro Pro Lys Thr Pro Arg Lys Thr Ala Ala 1 5 10 ACC GCC GCC GCT GCC GCC GCG GAA CCC CCG GCA CCG CCG CCG CCG CCC 219 Thr Ala Ala Ala Ala Ala Ala Glu Pro Pro Ala Pro Pro Pro Pro Pro 15 20 25 CCT CCT GAG GAG GAC CCA GAG CAG GAC AGC GGC CCG GAG GAC CTG CCT 267 Pro Pro Glu Glu Asp Pro Glu Gln Asp Ser Gly Pro Glu Asp Leu Pro 30 35 40 CTC GTC AGG CTT GAG TTT GAA GAA ACA GAA GAA CCT GAT TTT ACT GCA 315 Leu Val Arg Leu Glu Phe Glu Glu Thr Glu Glu Pro Asp Phe Thr Ala 45 50 55 TTA TGT CAG AAA TTA AAG ATA CCA GAT CAT GTC AGA GAG AGA GCT TGG 363 Leu Cys Gln Lys Leu Lys Ile Pro Asp His Val Arg Glu Arg Ala Trp 60 65 70 75 TTA ACT TGG GAG AAA GTT TCA TCT GTG GAT GGA GTA TTG GGA GGT TAT 411 Leu Thr Trp Glu Lys Val Ser Ser Val Asp Gly Val Leu Gly Gly Tyr 80 85 90 ATT CAA AAG AAA AAG GAA CTG TGG GGA ATC TGT ATC TTT ATT GCA GCA 459 Ile Gln Lys Lys Lys Glu Leu Trp Gly Ile Cys Ile Phe Ile Ala Ala 95 100 105 GTT GAC CTA GAT GAG ATG TCG TTC ACT TTT ACT GAG CTA CAG AAA AAC 507 Val Asp Leu Asp Glu Met Ser Phe Thr Phe Thr Glu Leu Gln Lys Asn 110 115 120 ATA GAA ATC AGT GTC CAT AAA TTC TTT AAC TTA CTA AAA GAA ATT GAT 555 Ile Glu Ile Ser Val His Lys Phe Phe Asn Leu Leu Lys Glu Ile Asp 125 130 135 ACC AGT ACC AAA GTT GAT AAT GCT ATG TCA AGA CTG TTG AAG AAG TAT 603 Thr Ser Thr Lys Val Asp Asn Ala Met Ser Arg Leu Leu Lys Lys Tyr 140 145 150 155 GAT GTA TTG TTT GCA CTC TTC AGC AAA TTG GAA AGG ACA TGT GAA CTT 651 Asp Val Leu Phe Ala Leu Phe Ser Lys Leu Glu Arg Thr Cys Glu Leu 160 165 170 ATA TAT TTG ACA CAA CCC AGC AGT TCG ATA TCT ACT GAA ATA AAT TCT 699 Ile Tyr Leu Thr Gln Pro Ser Ser Ser Ile Ser Thr Glu Ile Asn Ser 175 180 185 GCA TTG GTG CTA AAA GTT TCT TGG ATC ACA TTT TTA TTA GCT AAA GGG 747 Ala Leu Val Leu Lys Val Ser Trp Ile Thr Phe Leu Leu Ala Lys Gly 190 195 200 GAA GTA TTA CAA ATG GAA GAT GAT CTG GTG ATT TCA TTT CAG TTA ATG 795 Glu Val Leu Gln Met Glu Asp Asp Leu Val Ile Ser Phe Gln Leu Met 205 210 215 CTA TGT GTC CTT GAC TAT TTT ATT AAA CTC TCA CCT CCC ATG TTG CTC 843 Leu Cys Val Leu Asp Tyr Phe Ile Lys Leu Ser Pro Pro Met Leu Leu 220 225 230 235 AAA GAA CCA TAT AAA ACA GCT GTT ATA CCC ATT AAT GGT TCA CCT CGA 891 Lys Glu Pro Tyr Lys Thr Ala Val Ile Pro Ile Asn Gly Ser Pro Arg 240 245 250 ACA CCC AGG CGA GGT CAG AAC AGG AGT GCA CGG ATA GCA AAA CAA CTA 939 Thr Pro Arg Arg Gly Gln Asn Arg Ser Ala Arg Ile Ala Lys Gln Leu 255 260 265 GAA AAT GAT ACA AGA ATT ATT GAA GTT CTC TGT AAA GAA CAT GAA TGT 987 Glu Asn Asp Thr Arg Ile Ile Glu Val Leu Cys Lys Glu His Glu Cys 270 275 280 AAT ATA GAT GAG GTG AAA AAT GTT TAT TTC AAA AAT TTT ATA CCT TTT 1035 Asn Ile Asp Glu Val Lys Asn Val Tyr Phe Lys Asn Phe Ile Pro Phe 285 290 295 ATG AAT TCT CTT GGA CTT GTA ACA TCT AAT GGA CTT CCA GAG GTT GAA 1083 Met Asn Ser Leu Gly Leu Val Thr Ser Asn Gly Leu Pro Glu Val Glu 300 305 310 315 AAT CTT TCT AAA CGA TAC GAA GAA ATT TAT CTT AAA AAT AAA GAT CTA 1131 Asn Leu Ser Lys Arg Tyr Glu Glu Ile Tyr Leu Lys Asn Lys Asp Leu 320 325 330 GAT GCA AGA TTA TTT TTG GAT CAT GAT AAA ACT CTT CAG ACT GAT TCT 1179 Asp Ala Arg Leu Phe Leu Asp His Asp Lys Thr Leu Gln Thr Asp Ser 335 340 345 ATA GAC AGT TTT GAA ACA CAG AGA ACA CCA CGA AAA AGT AAC CTT GAT 1227 Ile Asp Ser Phe Glu Thr Gln Arg Thr Pro Arg Lys Ser Asn Leu Asp 350 355 360 GAA GAG GTG AAT GTA ATT CCT CCA CAC ACT CCA GTT AGG ACT GTT ATG 1275 Glu Glu Val Asn Val Ile Pro Pro His Thr Pro Val Arg Thr Val Met 365 370 375 AAC ACT ATC CAA CAA TTA ATG ATG ATT TTA AAT TCA GCA AGT GAT CAA 1323 Asn Thr Ile Gln Gln Leu Met Met Ile Leu Asn Ser Ala Ser Asp Gln 380 385 390 395 CCT TCA GAA AAT CTG ATT TCC TAT TTT AAC AAC TGC ACA GTG AAT CCA 1371 Pro Ser Glu Asn Leu Ile Ser Tyr Phe Asn Asn Cys Thr Val Asn Pro 400 405 410 AAA GAA AGT ATA CTG AAA AGA GTG AAG GAT ATA GGA TAC ATC TTT AAA 1419 Lys Glu Ser Ile Leu Lys Arg Val Lys Asp Ile Gly Tyr Ile Phe Lys 415 420 425 GAG AAA TTT GCT AAA GCT GTG GGA CAG GGT TGT GTC GAA ATT GGA TCA 1467 Glu Lys Phe Ala Lys Ala Val Gly Gln Gly Cys Val Glu Ile Gly Ser 430 435 440 CAG CGA TAC AAA CTT GGA GTT CGC TTG TAT TAC CGA GTA ATG GAA TCC 1515 Gln Arg Tyr Lys Leu Gly Val Arg Leu Tyr Tyr Arg Val Met Glu Ser 445 450 455 ATG CTT AAA TCA GAA GAA GAA CGA TTA TCC ATT CAA AAT TTT AGC AAA 1563 Met Leu Lys Ser Glu Glu Glu Arg Leu Ser Ile Gln Asn Phe Ser Lys 460 465 470 475 CTT CTG AAT GAC AAC ATT TTT CAT ATG TCT TTA TTG GCG TGC GCT CTT 1611 Leu Leu Asn Asp Asn Ile Phe His Met Ser Leu Leu Ala Cys Ala Leu 480 485 490 GAG GTT GTA ATG GCC ACA TAT AGC AGA AGT ACA TCT CAG AAT CTT GAT 1659 Glu Val Val Met Ala Thr Tyr Ser Arg Ser Thr Ser Gln Asn Leu Asp 495 500 505 TCT GGA ACA GAT TTG TCT TTC CCA TGG ATT CTG AAT GTG CTT AAT TTA 1707 Ser Gly Thr Asp Leu Ser Phe Pro Trp Ile Leu Asn Val Leu Asn Leu 510 515 520 AAA GCC TTT GAT TTT TAC AAA GTG ATC GAA AGT TTT ATC AAA GCA GAA 1755 Lys Ala Phe Asp Phe Tyr Lys Val Ile Glu Ser Phe Ile Lys Ala Glu 525 530 535 GGC AAC TTG ACA AGA GAA ATG ATA AAA CAT TTA GAA CGA TGT GAA CAT 1803 Gly Asn Leu Thr Arg Glu Met Ile Lys His Leu Glu Arg Cys Glu His 540 545 550 555 CGA ATC ATG GAA TCC CTT GCA TGG CTC TCA GAT TCA CCT TTA TTT GAT 1851 Arg Ile Met Glu Ser Leu Ala Trp Leu Ser Asp Ser Pro Leu Phe Asp 560 565 570 CTT ATT AAA CAA TCA AAG GAC CGA GAA GGA CCA ACT GAT CAC CTT GAA 1899 Leu Ile Lys Gln Ser Lys Asp Arg Glu Gly Pro Thr Asp His Leu Glu 575 580 585 TCT GCT TGT CCT CTT AAT CTT CCT CTC CAG AAT AAT CAC ACT GCA GCA 1947 Ser Ala Cys Pro Leu Asn Leu Pro Leu Gln Asn Asn His Thr Ala Ala 590 595 600 GAT ATG TAT CTT TCT CCT GTA AGA TCT CCA AAG AAA AAA GGT TCA ACT 1995 Asp Met Tyr Leu Ser Pro Val Arg Ser Pro Lys Lys Lys Gly Ser Thr 605 610 615 ACG CGT GTA AAT TCT ACT GCA AAT GCA GAG ACA CAA GCA ACC TCA GCC 2043 Thr Arg Val Asn Ser Thr Ala Asn Ala Glu Thr Gln Ala Thr Ser Ala 620 625 630 635 TTC CAG ACC CAG AAG CCA TTG AAA TCT ACC TCT CTT TCA CTG TTT TAT 2091 Phe Gln Thr Gln Lys Pro Leu Lys Ser Thr Ser Leu Ser Leu Phe Tyr 640 645 650 AAA AAA GTG TAT CGG CTA GCC TAT CTC CGG CTA AAT ACA CTT TGT GAA 2139 Lys Lys Val Tyr Arg Leu Ala Tyr Leu Arg Leu Asn Thr Leu Cys Glu 655 660 665 CGC CTT CTG TCT GAG CAC CCA GAA TTA GAA CAT ATC ATC TGG ACC CTT 2187 Arg Leu Leu Ser Glu His Pro Glu Leu Glu His Ile Ile Trp Thr Leu 670 675 680 TTC CAG CAC ACC CTG CAG AAT GAG TAT GAA CTC ATG AGA GAC AGG CAT 2235 Phe Gln His Thr Leu Gln Asn Glu Tyr Glu Leu Met Arg Asp Arg His 685 690 695 TTG GAC CAA ATT ATG ATG TGT TCC ATG TAT GGC ATA TGC AAA GTG AAG 2283 Leu Asp Gln Ile Met Met Cys Ser Met Tyr Gly Ile Cys Lys Val Lys 700 705 710 715 AAT ATA GAC CTT AAA TTC AAA ATC ATT GTA ACA GCA TAC AAG GAT CTT 2331 Asn Ile Asp Leu Lys Phe Lys Ile Ile Val Thr Ala Tyr Lys Asp Leu 720 725 730 CCT CAT GCT GTT CAG GAG ACA TTC AAA CGT GTT TTG ATC AAA GAA GAG 2379 Pro His Ala Val Gln Glu Thr Phe Lys Arg Val Leu Ile Lys Glu Glu 735 740 745 GAG TAT GAT TCT ATT ATA GTA TTC TAT AAC TCG GTC TTC ATG CAG AGA 2427 Glu Tyr Asp Ser Ile Ile Val Phe Tyr Asn Ser Val Phe Met Gln Arg 750 755 760 CTG AAA ACA AAT ATT TTG CAG TAT GCT TCC ACC AGG CCC CCT ACC TTG 2475 Leu Lys Thr Asn Ile Leu Gln Tyr Ala Ser Thr Arg Pro Pro Thr Leu 765 770 775 TCA CCA ATA CCT CAC ATT CCT CGA AGC CCT TAC AAG TTT CCT AGT TCA 2523 Ser Pro Ile Pro His Ile Pro Arg Ser Pro Tyr Lys Phe Pro Ser Ser 780 785 790 795 CCC TTA CGG ATT CCT GGA GGG AAC ATC TAT ATT TCA CCC CTG AAG AGT 2571 Pro Leu Arg Ile Pro Gly Gly Asn Ile Tyr Ile Ser Pro Leu Lys Ser 800 805 810 CCA TAT AAA ATT TCA GAA GGT CTG CCA ACA CCA ACA AAA ATG ACT CCA 2619 Pro Tyr Lys Ile Ser Glu Gly Leu Pro Thr Pro Thr Lys Met Thr Pro 815 820 825 AGA TCA AGA ATC TTA GTA TCA ATT GGT GAA TCA TTC GGG ACT TCT GAG 2667 Arg Ser Arg Ile Leu Val Ser Ile Gly Glu Ser Phe Gly Thr Ser Glu 830 835 840 AAG TTC CAG AAA ATA AAT CAG ATG GTA TGT AAC AGC GAC CGT GTG CTC 2715 Lys Phe Gln Lys Ile Asn Gln Met Val Cys Asn Ser Asp Arg Val Leu 845 850 855 AAA AGA AGT GCT GAA GGA AGC AAC CCT CCT AAA CCA CTG AAA AAA CTA 2763 Lys Arg Ser Ala Glu Gly Ser Asn Pro Pro Lys Pro Leu Lys Lys Leu 860 865 870 875 CGC TTT GAT ATT GAA GGA TCA GAT GAA GCA GAT GGA AGT AAA CAT CTC 2811 Arg Phe Asp Ile Glu Gly Ser Asp Glu Ala Asp Gly Ser Lys His Leu 880 885 890 CCA GGA GAG TCC AAA TTT CAG CAG AAA CTG GCA GAA ATG ACT TCT ACT 2859 Pro Gly Glu Ser Lys Phe Gln Gln Lys Leu Ala Glu Met Thr Ser Thr 895 900 905 CGA ACA CGA ATG CAA AAG CAG AAA ATG AAT GAT AGC ATG GAT ACC TCA 2907 Arg Thr Arg Met Gln Lys Gln Lys Met Asn Asp Ser Met Asp Thr Ser 910 915 920 AAC AAG GAA GAG AAA TGAGGATCTC AGGACCTTGG TGGACACTGT GTACACCTCT 2962 Asn Lys Glu Glu Lys 925 GGATTCATTG TCTCTCACAG ATGTGACTGT AT 2994 928 amino acids amino acid linear protein 2 Met Pro Pro Lys Thr Pro Arg Lys Thr Ala Ala Thr Ala Ala Ala Ala 1 5 10 15 Ala Ala Glu Pro Pro Ala Pro Pro Pro Pro Pro Pro Pro Glu Glu Asp 20 25 30 Pro Glu Gln Asp Ser Gly Pro Glu Asp Leu Pro Leu Val Arg Leu Glu 35 40 45 Phe Glu Glu Thr Glu Glu Pro Asp Phe Thr Ala Leu Cys Gln Lys Leu 50 55 60 Lys Ile Pro Asp His Val Arg Glu Arg Ala Trp Leu Thr Trp Glu Lys 65 70 75 80 Val Ser Ser Val Asp Gly Val Leu Gly Gly Tyr Ile Gln Lys Lys Lys 85 90 95 Glu Leu Trp Gly Ile Cys Ile Phe Ile Ala Ala Val Asp Leu Asp Glu 100 105 110 Met Ser Phe Thr Phe Thr Glu Leu Gln Lys Asn Ile Glu Ile Ser Val 115 120 125 His Lys Phe Phe Asn Leu Leu Lys Glu Ile Asp Thr Ser Thr Lys Val 130 135 140 Asp Asn Ala Met Ser Arg Leu Leu Lys Lys Tyr Asp Val Leu Phe Ala 145 150 155 160 Leu Phe Ser Lys Leu Glu Arg Thr Cys Glu Leu Ile Tyr Leu Thr Gln 165 170 175 Pro Ser Ser Ser Ile Ser Thr Glu Ile Asn Ser Ala Leu Val Leu Lys 180 185 190 Val Ser Trp Ile Thr Phe Leu Leu Ala Lys Gly Glu Val Leu Gln Met 195 200 205 Glu Asp Asp Leu Val Ile Ser Phe Gln Leu Met Leu Cys Val Leu Asp 210 215 220 Tyr Phe Ile Lys Leu Ser Pro Pro Met Leu Leu Lys Glu Pro Tyr Lys 225 230 235 240 Thr Ala Val Ile Pro Ile Asn Gly Ser Pro Arg Thr Pro Arg Arg Gly 245 250 255 Gln Asn Arg Ser Ala Arg Ile Ala Lys Gln Leu Glu Asn Asp Thr Arg 260 265 270 Ile Ile Glu Val Leu Cys Lys Glu His Glu Cys Asn Ile Asp Glu Val 275 280 285 Lys Asn Val Tyr Phe Lys Asn Phe Ile Pro Phe Met Asn Ser Leu Gly 290 295 300 Leu Val Thr Ser Asn Gly Leu Pro Glu Val Glu Asn Leu Ser Lys Arg 305 310 315 320 Tyr Glu Glu Ile Tyr Leu Lys Asn Lys Asp Leu Asp Ala Arg Leu Phe 325 330 335 Leu Asp His Asp Lys Thr Leu Gln Thr Asp Ser Ile Asp Ser Phe Glu 340 345 350 Thr Gln Arg Thr Pro Arg Lys Ser Asn Leu Asp Glu Glu Val Asn Val 355 360 365 Ile Pro Pro His Thr Pro Val Arg Thr Val Met Asn Thr Ile Gln Gln 370 375 380 Leu Met Met Ile Leu Asn Ser Ala Ser Asp Gln Pro Ser Glu Asn Leu 385 390 395 400 Ile Ser Tyr Phe Asn Asn Cys Thr Val Asn Pro Lys Glu Ser Ile Leu 405 410 415 Lys Arg Val Lys Asp Ile Gly Tyr Ile Phe Lys Glu Lys Phe Ala Lys 420 425 430 Ala Val Gly Gln Gly Cys Val Glu Ile Gly Ser Gln Arg Tyr Lys Leu 435 440 445 Gly Val Arg Leu Tyr Tyr Arg Val Met Glu Ser Met Leu Lys Ser Glu 450 455 460 Glu Glu Arg Leu Ser Ile Gln Asn Phe Ser Lys Leu Leu Asn Asp Asn 465 470 475 480 Ile Phe His Met Ser Leu Leu Ala Cys Ala Leu Glu Val Val Met Ala 485 490 495 Thr Tyr Ser Arg Ser Thr Ser Gln Asn Leu Asp Ser Gly Thr Asp Leu 500 505 510 Ser Phe Pro Trp Ile Leu Asn Val Leu Asn Leu Lys Ala Phe Asp Phe 515 520 525 Tyr Lys Val Ile Glu Ser Phe Ile Lys Ala Glu Gly Asn Leu Thr Arg 530 535 540 Glu Met Ile Lys His Leu Glu Arg Cys Glu His Arg Ile Met Glu Ser 545 550 555 560 Leu Ala Trp Leu Ser Asp Ser Pro Leu Phe Asp Leu Ile Lys Gln Ser 565 570 575 Lys Asp Arg Glu Gly Pro Thr Asp His Leu Glu Ser Ala Cys Pro Leu 580 585 590 Asn Leu Pro Leu Gln Asn Asn His Thr Ala Ala Asp Met Tyr Leu Ser 595 600 605 Pro Val Arg Ser Pro Lys Lys Lys Gly Ser Thr Thr Arg Val Asn Ser 610 615 620 Thr Ala Asn Ala Glu Thr Gln Ala Thr Ser Ala Phe Gln Thr Gln Lys 625 630 635 640 Pro Leu Lys Ser Thr Ser Leu Ser Leu Phe Tyr Lys Lys Val Tyr Arg 645 650 655 Leu Ala Tyr Leu Arg Leu Asn Thr Leu Cys Glu Arg Leu Leu Ser Glu 660 665 670 His Pro Glu Leu Glu His Ile Ile Trp Thr Leu Phe Gln His Thr Leu 675 680 685 Gln Asn Glu Tyr Glu Leu Met Arg Asp Arg His Leu Asp Gln Ile Met 690 695 700 Met Cys Ser Met Tyr Gly Ile Cys Lys Val Lys Asn Ile Asp Leu Lys 705 710 715 720 Phe Lys Ile Ile Val Thr Ala Tyr Lys Asp Leu Pro His Ala Val Gln 725 730 735 Glu Thr Phe Lys Arg Val Leu Ile Lys Glu Glu Glu Tyr Asp Ser Ile 740 745 750 Ile Val Phe Tyr Asn Ser Val Phe Met Gln Arg Leu Lys Thr Asn Ile 755 760 765 Leu Gln Tyr Ala Ser Thr Arg Pro Pro Thr Leu Ser Pro Ile Pro His 770 775 780 Ile Pro Arg Ser Pro Tyr Lys Phe Pro Ser Ser Pro Leu Arg Ile Pro 785 790 795 800 Gly Gly Asn Ile Tyr Ile Ser Pro Leu Lys Ser Pro Tyr Lys Ile Ser 805 810 815 Glu Gly Leu Pro Thr Pro Thr Lys Met Thr Pro Arg Ser Arg Ile Leu 820 825 830 Val Ser Ile Gly Glu Ser Phe Gly Thr Ser Glu Lys Phe Gln Lys Ile 835 840 845 Asn Gln Met Val Cys Asn Ser Asp Arg Val Leu Lys Arg Ser Ala Glu 850 855 860 Gly Ser Asn Pro Pro Lys Pro Leu Lys Lys Leu Arg Phe Asp Ile Glu 865 870 875 880 Gly Ser Asp Glu Ala Asp Gly Ser Lys His Leu Pro Gly Glu Ser Lys 885 890 895 Phe Gln Gln Lys Leu Ala Glu Met Thr Ser Thr Arg Thr Arg Met Gln 900 905 910 Lys Gln Lys Met Asn Asp Ser Met Asp Thr Ser Asn Lys Glu Glu Lys 915 920 925 

What is claimed is:
 1. A method of controlling cancer suppression in a mammal having a cancer suppressing gene, comprising the steps of: making a substantially duplicated genetic material corresponding to the genetic material of said gene, the substantially duplicated material selected from the group consisting of a cloned cancer suppressing gene, a modified or defective cancer suppressing gene, homologues thereof, fragments thereof, and mixtures thereof; and interchanging said duplicated genetic material and the cancer suppressing gene of the mammal.
 2. A method of claim 1, wherein before said making a substantially duplicated genetic material, determining the chromosomal location of said cancer suppressing gene of the mammal.
 3. A method of claim 1, wherein after said making a substantially duplicated genetic material, detecting the presence or absence of an inactive cancer suppressing gene of a tissue sample of the mammal to determine whether or not the tissue sample cancer suppressing gene is defective or absent.
 4. A method of claim 3, wherein in response to a determination that the tissue sample cancer suppressing gene is either defective or absent, replacing a cancer suppressing gene of the mammal with its clone.
 5. A method of claim 3, wherein the determination of whether or not the tissue sample cancer suppressing gene is defective or absent is accomplished by measuring the amount of protein product of said cancer suppressing gene, of the tissue sample, bound by an antibody specific for said protein.
 6. A method of claim 5, wherein the determination of whether or not the tissue sample cancer suppressing gene is defective or absent is accomplished by: (a) labeling said tissue sample with radioactive isotope; (b) lysing the labeled tissue; (c) reacting the protein product of said cancer suppressing gene with an antibody specific for said protein thereby forming a protein/antibody immunocomplex; (d) autoradiographing the immunocomplex obtained in step (c); and (e) determining the presence or absence of the protein product by comparing the autoradiogram of step (d) with the autoradiogram of the standard protein product.
 7. The method of claim 5, wherein the determination of whether or not the tissue sample cancer suppressing gene is defective or absent is accomplished by enzyme immunoassay techniques.
 8. The method of claim 5, wherein the determination of whether or not the tissue sample cancer suppressing gene is defective or absent is accomplished by immunocytochemistry methods.
 9. The method of claim 5, wherein the cancer suppressing gene is the RB gene and the protein product is ppRB¹¹⁰.
 10. The method of claim 1, wherein said cancer suppressing gene is replaced with substantially duplicated material selected from the group consisting of said cloned cancer suppressing gene, homologues thereof, fragments thereof, and mixtures thereof, for therapeutic purposes.
 11. The method of claim 1, wherein said cancer suppressing gene is replaced with substantially duplicated material selected from the group consisting of said defective cancer suppressing gene, homologues thereof, fragments thereof, and mixtures thereof, for facilitating the testing of the carcinogenicity of environmental influences.
 12. The method of claim 2, wherein the location of said cancer suppressing gene is determined by chromosome walking.
 13. The method of claim 2, wherein the location of said cancer suppressing gene is determined through organic markers.
 14. A method of claim 2, wherein: said chromosomal location of said cancer suppressing gene is determined by testing genes of a chromosome for phenotypic expression; determining one of the genes of said chromosome to be a marker gene; and using chromosomal walking techniques to locate a cancer suppressing gene.
 15. An animal genetically altered so as to have the allele of at least one cancer suppressing gene selected from the group consisting of a defective allele, a homologue thereof, a fragment thereof, and a mixture thereof.
 16. An animal of claim 15, wherein said defective allele is selected from the group consisting of defective alleles of RB genes, breast cancer suppressing genes, Wilm's tumor suppressing genes, Beckwith-Wiedemann syndrome suppressing genes, bladder transitional cell carcinoma suppressing genes, neuroblastoma suppressing genes, small cell lung carcinoma suppressing genes, renal cell carcinoma suppressing genes, acoustic neuroma suppressing genes, colorectal carcinoma suppressing genes, homolgues thereof, fragments thereof, and mixtures thereof.
 17. An animal of claim 15, wherein said allele contains a DNA fragment having at least one defective nucleotide sequence.
 18. An animal of claim 15, wherein said defective allele contains a DNA fragment having at least one defective RB nucleotide sequence.
 19. The animal of claim 15, wherein said animal is a mouse.
 20. A method for determining the carcinogenicity of suspected environmental influences, using the animal of claim 14, comprising the steps of: exposing said animal to a suspected environmental influence; observing the animal for the phenotypic expression of cancer; and determining carcinogenicity of the suspected environmental influence in response to observing a phenotypic expression of cancer in the animal.
 21. A method of claim 20, wherein said exposing includes exposing to a source of radiation.
 22. A method of claim 20, wherein said exposing includes exposing to tobacco combustion products.
 23. A method of claim 20, wherein said exposing includes exposing to food additives.
 24. A method of claim 20, wherein said exposing includes exposing to artificial substances.
 25. A method of claim 20, wherein said observing includes examining the animal for tumor development.
 26. A method of claim 25, wherein in response to the formation of a tumor in the animal, analyzing the tumor for the presence of cancer cells.
 27. A method of making the animal of claim 15, comprising: using at least one allele of an animal cancer suppressing gene selected from the group consisting of a defective allele, a homologue thereof, a fragment thereof, and a mixture thereof; mutating at least one animal cell with said allele to form a mutated cell; introducing said mutated cell into an animal blastocyst; permitting growth of the blastocyst for a given period of time sufficient to incorporate said allele into its cells; repressing genetic recombinations within said cells; transferring the blastocyst containing said allele into the uterus of a pseudo pregnant animal for giving birth subsequently to an animal bearing said allele; breeding said animal to reproduce additional animals; and selecting the animal of claim 14 from said additional animals by determining the presence therein of the said allele.
 28. A method of claim 27, wherein before introducing said allele, removing said blastocyst from a super ovulated animal, and wherein said blastocyst is comprised of undifferentiated cells.
 29. A method of claim 27, wherein said introducing is performed in vitro.
 30. A pharmaceutical composition wherein the active ingredient is selected from the group consisting of a naturally occurring intact cancer suppressing gene, a cloned intact cancer suppressing gene, fragments thereof, homolgues thereof and mixtures thereof.
 31. A pharmaceutical composition of claim 30, wherein said naturally occurring and cloned cancer suppressing gene is selected from the group consisting of RB genes, breast cancer suppressing genes, Wilm's tumor suppressing genes, Beckwith-Wiedemann syndrome suppressing genes, bladder transitional cell carcinoma suppressing genes, neuroblastoma suppressing genes, small cell lung carcinoma suppressing genes, renal cell carcinoma suppressing genes, acoustic neuroma suppressing genes, colorectal carcinoma suppressing genes, homolgues thereof, fragments thereof, and mixtures thereof.
 32. A pharmaceutical composition of claim 30, wherein the active ingredient is selected from the group consisting of RB cDNA, modified RB cDNA fragment, clones thereof, homolgues thereof and mixtures thereof.
 33. A pharmaceutical composition of claim 31, wherein the active ingredient for each of said gene is selected from the group consisting od cDNA of said gene, fragments of said cDNA, homologues thereof and mixtures thereof.
 34. A pharmaceutical composition of claim 32, wherein the cancer suppressing gene is isolated from human chromosome 13 region 13q14.
 35. A pharmaceutical composition of claim 31, wherein the cancer suppressing gene and its clone each has the following nucleotide sequence: TTCCGGTTTTTCTCAGGGGACGTTGAAATTATTTTTGTAACGGGAGTCGGGGAGAGGACGGGGCGTGCCCCGCGTGCGCGCGCGTCGTCCTCCCGGCGCTCCTCCACAGCTCGCTGGCTC 120 CCGCCGCGGAAAGGCGTCATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCGGCTGCCGCCGCCGGAACCCCCGGCACCGCCGCCGCCGCCCCCTCCGTAGGAGGACCCAGAG 210                    

  P  P  K  T  P  R  K  T |A  A  T  A  A  A  A  A  A| K |P  P  A  P  P  P  P  P  P  P| E  E  D  P  E (34) CAGGACAGCGGCCCGGAGGACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTATGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCT 360  Q  Q  S  G  P  E  D  L  P  L  V  A  L  E  F  F  T  E  E  P  D  F  T  A  L  C  Q  K  L  K  I  P  D  N  V  R  E  R  A (74) TGGTTAACTTGGGAGAAAAGTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGAATCTGTATCTTTATTGCAGCAGTTGACCTAGATGAGATGTCG 410  W  L  T  W  R  K  V  S  S  V  D  O  V  L  G  R  Y  I  G  K  K  K  L  L  W  O  I  C  I  F  I  A  A  V  G  L  D  E  

  S (114) TTCACTTTTACTGAGCTACAGAAAAACATAGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACCAGTACCAAAGTTGATAATGCTATGTCAAGAGTATTGAAGAAG 600  F  T  F  T  E  L  S  K  N  I  E  I  E  V  N  K  F  F  N  L  L  K  E  I  D  T  S  Y  K  V  D  K  A  M  S  A  L  L  K  K (134) TATGATGTATTGTTTGCACTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCGATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAATTTCT 720  Y  D  V  L  F  A  L  F  S  K  L  E  A  I  C  N  L  I  Y  L  T  Q  P  E  S  S  I  S  T  E  I  N  S  A  L  V  L  K  Y  S (196) TGGATCACATTTTTATTAGCTAAAGCGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTATGTGTCCTTGAGTATTTTATTAAACTCTCACCTCCCATGTTG 848  W  I  I  F  L  L  A  K  G  E  V  L  G  M  E  D  G  L  V  I  S  F  Q  L  M  L  C  V  L  D  T  F  I  K  L  S  P  P  N  L (234) CTCAAAGAACCATATAAAACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGTGCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATT 960  L  K  E  P  T  K  T  A  V  I  P  I  N  G  S  P  R  T  P  R  R  G  Q  M  R  S  A  R  I  A  K  G  L  E  N  D  T  R  I  I (274) GAAGTTCTCTGTAAAGAACATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATGAATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTT 1064  E  V  L  C  K  E  N  E  C  M  I  D  E  V  K  M  V  Y  F  K  M  F  I  P  F  M  N  S  L  G  L  Y  T  S  N  G  L  P  E  V (334) GAAAATCTTTCTAAACGATACGAAGAAATTTATCTTAAAAATAAAGATCTAGATGCAAGATTATTTTTGGATCTGATAAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAG 1200  E  N  L  S  K  R  T  E  E  I  Y  L  K  N  K  D  L  D  A  R  L  F  L  D  K  D  K  I  L  Q  T  D  S  T  D  G  F  K  T  Q (334) AGAACACCACGAAAAAGTAACCTTGATGAAGAGGTGAATGTAATTCGTCCACACAGTGCAGTTAGGACTGTTATGAACAGTATCCAACAATTAATGATGATTTTAAATTCAGCAAATGAT 1320  N  T  P  R  K  S  N  L  D  E  E  V  K  V  I  P  P  K  I  P  V  R  T  V  M  N  T  I  G  G  L  K  K  I  L  K  S  A  S  D (394) CAACCTTCAGAAAATCTGATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAGGATATAGGATACATCTTTAAAGAGAAATTTGCTAAACTGTG 1418  Q  P  S  E  N  L  I  S  Y  F  H  K  C  T  V  N  P  K  E  S  I  L  K  R  V  K  D  I  G  Y  I  F  K  E  K  F  A  K  A  V (434) CGACAGGGTTGTGTCGAAATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATGCTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGC 1340  G  G  G  C  V  E  I  S  S  Q  R  Y  K  L  G  V  R  L  Y  Y  R  V  M  E  S  M  L  K  S  E  E  E  K  L  S  I  Q  N  F  S 474) AAACTTCTGAATGACAACATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGAAGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTC 1680  K  L  L  N  D  H  I  F  N  M  S  L  L  A  C  A  L  E  Y  Y  M  A  T  Y  S  R  S  T  S  Q  N  L  D  S  G  T  D  L  S  F (314) AAACTTCTGAATGACAACATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGAAGTACATCTCAGAATCTTGATTCTGGAACAGATTTCTCTTTC 1680  K  L  L  N  D  N  I  F  N  M  S  L  L  A  C  A  L  E  Y  Y  M  A  T  Y  S  R  S  T  S  Q  H  L  D  S  G  T  D  L  S  F (316) CCATGGATTCTGAATGTGCTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGCAACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAA 1800  P  W  I  L  N  V  L  N  L  K  A  F  D  F  Y  K  V  I  N  S  F  I  K  A  K  G  M  L  T  R  E  M  I  K  N  L  R  R  G  K (354) CATCGAATCATGGAATCCCTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAAGGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTT 1420  K  R  I  M  E  S  L  A  W  L  S  D  L  F  L  F  D  L  I  K  Q  G  K  D  R  E  Q  P  T  D  N  L  E  S  A  C  F  L  N  L (394) CCTCTCCAGAATAATCACACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACGCGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCA 2040  F  L  Q  N  N  N  T  A  A  D  M  Y  L  S  P  Y  R  S  P  K  K  K  G  S  T  T  R  V  N  S  T  A  K  A  E  T  Q  A  T  S (634) CCCTTCCAGACCCAGAAGCCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCCGCTAGCCTATCTCCGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCA 2140  A  F  Q  T  Q  K  P  L  K  S  T  S  L  S  L  F  Y  K  K  V  Y  K  L. A  Y  L  A  L  N  T  L  C  K  K  L  L  S  E  N  P (474) GAATTAGAACATATCATCTGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTGGACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTG 2230  E  L  E  N  I  I  W  I  L  F  Q  H  T  L  Q  K  E  T  E  L  M  R  D  R  N  L  D  Q  I  M  M  C  S  M  Y  S  I  C  K  V (714) AAGAATATAGACCTTAAATTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAACGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTA 2400  K  M  I  D  L  K  F  K  I  I  Y  T  A  Y  K  D  L  P  N  A  W  Q  E  T  F  K  A  V  L  I  K  E  E  E  T  D  S  I  I  V (734) TTCTATAACTCGGTCTTCATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCACCAATACCTCAGATCCTCGAAGCCCTTACAAATTTCCTAGT 2920  F  T  N  E  V  F  N  Q  R  L  K  T  H  I  L  Q  T  A  S  T  K  F  P  T  L  S  P  I  P  K  I  P  R  S  P  Y  K  F  P  S (774) TCACCCTTACGGATTCCTGGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCAACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCA 3440  S  P  L  R  I  P  Q  G  N  I  Y  I  S  P  L  K  S  P  Y  K  I  S  E  Q  L  P  T  P  T  K  M  T  P  R  S  R  I  L  Y  S (834) ATTCGTGAATCATTCGGGACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAAAGAAGTGCTGAAGGAAGCAACCCTCCTAAACCAGTGAAAAAA 3760  I  C  E  S  F  Q  T  S  E  K  F  Q  K  I  N  Q  M  V  C  M  S  Q  R  V  L  K  A  S  A  K  K  S  N  P  P  K  P  L  K  K (874) CTACGCTTTGATATTGAAGGATCAGATGAGGCAGATGGAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAACTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAG 3330  L  R  F  D  I  E  Q  S  O  C  A  D  Q  S  K  M  L  P  G  E  S  K  F  Q  Q  X  L  A  E  M  I  S  Y  R  T  R  M  Q  K  Q (914) AAAATGAATGATAGCATGGATACCTCAAACAAGGAAGAGAAATGAGGATCTCAGGACCTTGGTGGACACTGTGTACACCTCTGGATTCATTGTCTCTCACAGATGTGACTGTAT . . .10 4737  K  M  N  D  S  M  D  T  S  N  K  E  E  K (926)


36. A pharmaceutical composition of claim 32, wherein said RB cDNA fragment is selected from the group consisting of RB-1, RB-2, RB-5, _(y)79R8 and mixtures thereof.
 37. A pharmaceutical composition of claim 32, wherein a resulting mRNA transcript of said RB cDNA fragment has 4.6 kb.
 38. A pharmaceutical composition of claim 37, wherein the cloned genomic DNA has at least 27 exons.
 39. A pharmaceutical composition of claim 30, wherein the cloned RB cDNA transcribes into mRNA which translates in protein having an amino acid sequence comprising:            

P P K T P R K T|A A T A A A A A A|E|P P A P P P P P P P|Z E D P E ( 34) Q D S G P E D L P L V R L E F E E T E E P D F T A L C Q K L K I P D H V R E R A ( 74) W L T W E K V S S V D G V L G G Y I G K K K E L W G I C I F I A A V D L D E

S (224) F T F T E L Q K H I E I S V H X F F H L L K E I D T S T K V D H A H S R L L K K (154) Y D V L F A L F S K L E R T C E L I Y L T Q P S S S I S T E I N S A L V L K V S (194) W I T F L L A K G E V L Q M E D D L V I S F Q L N L C V L D Y F I K L S F P M L (234) L K E P Y K T A V I F I N G S P R T P R R G Q N R S A R I A K Q L E N D T R I I (274) E V L C K E H E C H I D E V K H V Y F K H F I P F H N S L G L V T S N G L P E V (324) E H L S K R Y E E I Y L K N K D L D A R L F L D H D K T L Q T D S I D S F E T Q (354) R T F R K S H L D E E V N V I P P H T P V R T V H N T I Q Q L M H I L N S A S D (394) Q P S E N L I S Y F H N C T V N P K E S I L K R V K D I G Y I F K E K F A K A V (434) G Q G C V E I G S Q R Y K L G V R L Y Y R V H E S M L K S E E E R L S I Q H F S (474) K L L N D H I F H M S L L A C A L E V V M A T Y S R S T S Q N L D S G T D L S F (524) P W I L N V L N L K A F D F Y K V I E S F I K A E G N L T R E M I K H L E R C E (554) H R I H E S L A W L S D S F L F D L I K Q S K D R E G P T D H L E S A C P L N L (594) P L Q N N H T A A D H Y L S F V R S P K K K G S T T R V N S T A H A E T Q A T S (634) A F Q T Q K P L K S T S L S L F Y K K V Y R L A Y L R L N T L C E R L L S E H P (674) E L E H I I W T L F Q H T L Q N E Y E L H R D R H L D Q I M M C S M Y G I C K V (724) K N I D L K F K I I V T A Y K D L P H A V Q E T F K R V L I K E E E Y D S I I V (754) F Y H S V F M Q R L K T H I L Q Y A S T R P P T L S P I P H I P R S P Y K F P S (794) S P L R I P G G H I Y I S P L K S P Y K I S E G L P T P T K M T P R S R I L V S (834) I G E S F G T S E K F Q K I N Q M V C N S D R V L K R S A E G S N P P K P L K K (874) L R F D I E G S D E A D G S K H L P G E S K F Q Q K L A E M T S T R T R M Q K Q (914) K M H D S M D T S N K E E K (928) Sinlge-letter abbreviations for the amino acid residues are: A, Ala; C, Cys;. D, Asp; E, Gly; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg S, SER; T, Thr; V, Val; W, Trp; and Y, Tyr.


40. A DNA nucleotide sequence comprising: TTCCGGTTTTTCTCAGGGGACGTTGAAATTATTTTTGTAACGGGAGTCGGGAGAGGACGGGGCGTGCCCCGCGTGCGCGCGCGTCGTCCTCCCCGGCGCTCCTCCACAGCTCGCTGGCTC 729 CCGCCGCGGAAAGGCGTCATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCCCTGCCGCCGCGGAACCCCCGGCACCGCCGCCGCCGCCCCCTCCGTAGGAGGACCCAGAG 240                    

 P  P  K  T  P  R  K  T |A  A  T  A  A  A  A  A  A  | K |P  P  A  P  P  P  P  P  P  P| E  E  D  P  C (34) CAGGACAGCGGCCCGGAGGACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTATGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCT 340  Q  Q  S  G  P  E  D  L  P  L  V  R  L  E  F  E  E  T  E  E  P  O  F  T  A  L  C  Q  K  L  K  I  P  D  K  V  R  E  R  A (74) TGGTTAACTTGGGAGAAAGTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGAATCTGTATCTTTATTGCAGCAGTTGACCTAGATGAGATGTCG 480  W  L  T  W  E  K  V  S  S  V  D  G  V  L  G  G  Y  I  Q  K  X  K  E  L  W  G  I  C  I  F  I  A  A  V  D  L  D  E 

 S (114) TTCACTTTTACTGAGCTACAGAAAAACATAGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACCAGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAG 600  F  T  F  T  E  L  Q  K  N  I  E  I  E  V  K  K  F  F  N  L  L  K  E  I  D  T  S  T  K  V  D  N  A  N  S  R  L  L  K  K (134) TATCATGTATTGTTTGCACTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCGATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCT 720  Y  D  V  L  F  A  L  F  S  K  L  E  R  T  C  E  L  I  Y  L  T  Q  P  S  E  S  I  S  T  E  I  K  S  A  L  Y  L  K  V  S (194) TGGATCACATTTTTATTAGCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATCGTATGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTG 840  W  I  T  F  L  L  A  K  G  E  V  L  Q  M  E  D  D  L  Y  I  S  F  Q  L  M  L  C  Y  L  D  Y  F  I  K  L  S  P  P  M  L (234) CTCAAAGAACCATATAAAACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGTGCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATT 960  L  K  E  P  T  K  T  A  V  I  P  I  N  Q  S  F  R  T  F  R  R  Q  Q  M  R  S  A  R  I  A  K  Q  L  S  N  D  T  R  I  I (274) CAAGTTCTCTGTAAAGAACATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATGAATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTT 1040  E  V  L  C  K  E  N  E  C  M  I  D  E  V  K  K  Y  Y  F  K  N  F  I  F  F  M  W  S  L  S  L  V  T  S  N  Q  L  P  E  V (314) GAAAATCTTTCTAAACGATACGAAGAAATTTATCTTAAAAATAAAGATCTAGATGCAAGATTATTTTTGGATCATGATAAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAG 1200  E  M  L  S  K  A  T  E  E  I  Y  L  K  N  K  D  L  D  A  R  L  F  L  D  M  D  K  T  L  Q  T  D  S  I  D  S  F  E  T  N (334) AGAACACCACGAAAAAGTAACCTTGATGAAGAGGTGAATGTAATTCCTCCACACACTCCAGTTAGGACTGTTATGAACACTATCCAACAATTAATGATGATTTTAAATTCAGCAAGTAAT 1320  E  T  P  R  K  S  W  L  D  E  E  Y  N  V  I  P  P  W  T  F  V  R  T  V  M  N  T  I  Q  Q  L  M  M  I  L  K  S  A  L  D (394) CAACCTTCAGAAAATCTGATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAGGATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTG 1440  Q  P  S  E  N  L  I  S  T  F  N  N  C  T  V  N  P  K  X  S  I  L  K  R  V  K  D  I  G  Y  I  F  K  K  K  F  A  K  A  V (434) CGACAGGGTTGTGTCGAAATTGGATCACAGCGATACAAACTTGGAGTTCGGTTGTATTACCGAGTAATGGAATCCATGCTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGC 1360  S  Q  S  C  Y  E  I  S  S  S  R  Y  K  L  Q  Y  R  L  Y  Y  R  V  N  E  S  M  L  K  S  E  E  E  R  L  S  I  Q  N  F  S (474) AAACTTCTGAATGACAACATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGATAATGGCCACATATAGCAGAAGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTC 1480  K  L  L  N  D  N  I  F  N  M  S  L  L  A  C  A  L  E  V  V  M  A  T  Y  S  R  S  T  S  Q  M  L  D  S  S  T  D  L  S  F (314) CCATGGATTCTGAATGTGCTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGCAACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAA 1800  P  W  I  L  N  Y  L  N  L  K  A  F  D  F  Y  K  V  I  K  S  F  I  K  A  E  G  N  L  T  R  E  N  I  K  R  L  E  R  C  E (334) CATCGAATCATGGAATCCCTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAAGGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTT 1920  M  N  I  M  E  S  L  A  W  L  S  D  S  P  L  F  D  L  I  K  Q  S  K  D  R  S  Q  P  T  D  N  L  E  S  A  C  P  L  N  L (394) CCTCTCCAGAATAATCACAGTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACGCGTGTAAATTCTAGTGCAAATGCAGAGACACAAGCAACCTCA 2040  P  L  Q  M  M  M  T  A  A  D  N  Y  L  S  P  V  R  S  P  K  K  K  Q  S  T  T  R  V  N  S  T  A  K  A  E  T  Q  A  T  S (634) CCCTTCCAGACCCAGAAGCCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTCCGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCA 2160  A  F  Q  T  Q  K  P  L  K  S  T  S  L  S  L  F  Y  K  K  V  T  R  L  A  Y  L  R  L  N  T  L  C  E  R  L  L  S  E  N  P (674) CAATTAGAACATATCATCTGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTGGACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTG 2280  E  L  E  N  I  I  W  T  L  F  Q  N  T  L  Q  K  E  T  E  L  K  K  D  R  N  L  D  Q  I  M  M  C  S  M  T  G  I  C  K  V (714) AAGAATATAGACCTTAAATTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAACGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTA 2400  K  N  I  D  L  K  F  K  I  I  V  T  A  T  K  D  L  P  M  A  V  Q  E  T  F  K  R  V  L  I  K  E  E  E  Y  D  S  I  I  V (734) TTCTATAACTCGGTCTTCATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCACCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGT 2320  F  Y  N  S  V  F  N  Q  R  L  K  T  N  I  L  Q  T  A  S  T  R  P  P  T  L  S  F  I  P  N  I  P  R  S  P  Y  K  F  F  S (794) TCACCCTTACGGATTCCTGGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCAACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCA 2640  S  P  L  R  I  P  Q  G  M  I  T  I  S  P  L  K  S  P  T  K  I  S  E  Q  L  P  T  P  T  K  M  T  P  R  S  R  I  L  V  S (834) ATTGGTGAATCATTCGGGACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGGTGCTCAAAAGAAGTGCTGAAGGAAGCAACCCTCCTAAACCAGTGAAAAAAA 2760  I  G  E  S  F  Q  T  S  E  K  F  Q  K  I  M  Q  M  V  C  M  S  D  R  V  L  K  R  S  A  E  Q  S  K  P  P  K  F  L  K  K (674) CTACGCTTTGATATTGAAGGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAACTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAG 2880  L  R  F  D  I  E  S  S  D  E  A  D  G  S  K  N  L  P  Q  E  S  K  F  Q  Q  K  L  A  E  M  T  S  T  A  T  R  M  Q  K  Q (914) AAAATGAATGATAGCATGGATACCTCAAACAAGGAAGAGAAATGAGGATCTCAGGACCTGGTGGACACTGTGTACACCTCTGGATTCATTGTCTCTCACAGATGTGACTGTAT . . . 10 4737  K  M  N  D  E  M  S  T  S  M  K  S  E  K (926)


41. A method of therapeutically treating inactive, mutative or absent cancer suppressing genes comprising: treating said inactive, mutative or absent cancer suppressing genes with at least a portion of intact cancer suppressing genes.
 42. A method of claim 41, wherein said cancer suppressing genes are each a substance selected from the groups consisting of RB genes, breast cancer suppressing genes, Wilm's tumor suppressing genes, Beckwith-Wiedemann syndrome suppressing genes, bladder transitional cell carcinoma suppressing genes, neuroblastoma suppressing genes, small cell lung carcinoma suppressing genes, renal cell carcinoma suppressing genes, acoustic neuroma suppressing genes, colorectal carcinoma suppressing genes, and mixtures thereof.
 43. A method of claim 41, wherein said treating includes: treating said inactive, mutative or absent cancer suppressing gene with a substance selected from the group consisting of an RB gene, a portion of said gene, or a mixture thereof.
 44. A method of claim 43, wherein said portion is selected from the group consisting of RB cDNA, RB cDNA fragment, homologues thereof and mixtures thereof.
 45. The method of claim 41, wherein the intact cancer suppressing gene, or portion thereof, is delivered to the site of a tumor by means of a retrovirus.
 46. A method of claim 41, wherein the intact cancer suppressing gene, or a portion thereof, is delivered to the site of a tumor by a liposome.
 47. A method of claim 41, wherein the location of said cancer suppressing gene is determined by utilizing a genetic marker. 